

## The Cell A Molecular Approach 9th Edition PDF

Visit the link below to download the full version of the ebook

# [DOWNLOAD NOW](#)

# The Cell

## A Molecular Approach

NINTH EDITION



Geoffrey M. Cooper • Kenneth W. Ad...




Scan to Download  
or Type the Link

[ebook.ac/cell9e](http://ebook.ac/cell9e)

# The Cell

## A Molecular Approach

NINTH EDITION



Geoffrey M. Cooper • Kenneth W. Adams

# The Cell

## A Molecular Approach


NINTH EDITION



# The Cell

## A Molecular Approach


NINTH EDITION



**Geoffrey M. Cooper**  
Professor Emeritus  
*Boston University*

**Kenneth W. Adams**  
Associate Professor  
*Bridgewater State University*

**OXFORD**  
UNIVERSITY PRESS



### The Cover

The cover image shows the surface of a CART cell (left) recognizing the surface of an acute lymphoblastic leukemia (ALL) cell (right) and the release of toxic factors from the CART cell that penetrate and kill the leukemia. CART cells are engineered T cells that are remarkably effective for this particular form of cancer, leading to remission for most of the patients.

### The Artist

David S. Goodsell, is a Professor of Computational Biology at the Scripps Research Institute and Research Professor at Rutgers University, where he is the Scientific Outreach Lead at the RCSB Protein Data Bank. His illustrated books, *The Machinery of Life* and *Our Molecular Nature*, explore biological molecules and their diverse roles within living cells, and his book *Bionanotechnology: Lessons from Nature*, presents the growing connections between biology and nanotechnology. More information may be found at: <https://ccsb.scripps.edu/goodsell>

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Oxford is a registered trademark of Oxford University Press in the UK and certain other countries.

Published in the United States of America by Oxford University Press  
198 Madison Avenue, New York, NY 10016, United States of America

Copyright © 2023, 2019 Oxford University Press

Copyright © 2016, 2014, 2010, 2007, 2004, 2001, 1997 Sinauer Associates

For titles covered by Section 112 of the US Higher Education Opportunity Act, please visit [www.oup.com/us/he](http://www.oup.com/us/he) for the latest information about pricing and alternate formats.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, by license, or under terms agreed with the appropriate reproduction rights organization.

Inquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above.

You must not circulate this work in any other form and you must impose this same condition on any acquirer.

Address editorial correspondence to:

Oxford University Press  
23 Plumtree Road  
Sunderland, MA 01375 U.S.A.

Library of Congress Cataloging-in-Publication Data

**Names:** Cooper, Geoffrey M., author. | Adams, Kenneth W., author.

**Title:** The cell : a molecular approach / Geoffrey M. Cooper, Kenneth W. Adams.

**Description:** Ninth edition. | New York, NY : Oxford University Press, [2023] | Cooper's name appears first on the earlier edition. | Includes bibliographical references and index. | Summary: "Even the most experienced instructor can find teaching cell biology daunting, and most cell biology texts are bogged down in detail or background information. Lost in all the details are the more fascinating material and contemporary advances that represent this rapidly moving field. With so much to cover, creating a classroom around active learning may be difficult or nearly impossible. *The Cell: A Molecular Approach, Ninth Edition*, endeavors to address those issues with succinct writing, incorporation of current research, a test bank that encourages critical thinking, and an active learning framework. With just enough detail for a one-semester, sophomore/junior level course, the text presents fundamental concepts and current research, including chapters on Genomics and Transcriptional Regulation and Epigenetics, and in-text boxed features on Molecular Medicine, Key Experiments, and Interactive Data Analysis Problems. Finally, for instructors who want to flip their classrooms or just get students more engaged, *The Cell, Ninth Edition*, is the only cell biology text that is accompanied by an Active Learning Guide. This chapter-by-chapter playbook shows instructors how to create a dynamic learning environment with in-class exercises, clicker questions, and links to relevant media, animations, testing, and self-quizzing, all aligned with the new in-text learning objectives, wherever appropriate. This text provides the right level of detail, student engagement, and instructor support for the modern cell biology classroom"— Provided by publisher.

**Identifiers:** LCCN 2022018787 | ISBN 9780197583722 (hardcover) | ISBN 9780197583913 (epub)

**Subjects:** MESH: Cells | Cell Biology | Molecular Biology | Cell Physiological Phenomena

**Classification:** LCC QH581.2 | NLM QU 300 | DDC 571.6--dc23/eng/20220711  
LC record available at <https://lccn.loc.gov/2022018787>

9 8 7 6 5 4 3 2 1

Printed in the United States of America

# Brief Contents

## **PART 1 Fundamentals and Foundations 1**

- CHAPTER 1 Introduction to Cells and Cell Research 1
- CHAPTER 2 Physical Principles Underlying Cell Structure and Function 40
- CHAPTER 3 Fundamentals of Molecular Biology 84

## **PART 2 The Flow of Genetic Information 135**

- CHAPTER 4 Genes and Genomes 135
- CHAPTER 5 Replication, Maintenance, and Rearrangements of Genomic DNA 162
- CHAPTER 6 RNA Synthesis and Processing 199
- CHAPTER 7 Transcriptional Regulation and Epigenetics 230
- CHAPTER 8 Protein Synthesis, Processing, and Regulation 263
- CHAPTER 9 Genomics, Proteomics, and Systems Biology 304

## **PART 3 Subcellular Structures and Functions 336**

- CHAPTER 10 The Nucleus 336
- CHAPTER 11 Protein Processing and Sorting: The Endoplasmic Reticulum, Golgi Apparatus, and Lysosomes 365
- CHAPTER 12 Mitochondria, Chloroplasts, and Peroxisomes 411
- CHAPTER 13 The Cytoskeleton and Cell Movement 458
- CHAPTER 14 The Plasma Membrane 502
- CHAPTER 15 Cell Walls, the Extracellular Matrix, and Cell Interactions 542

## **PART 4 Cell Regulation 563**

- CHAPTER 16 Cell Signaling 563
- CHAPTER 17 The Cell Cycle 598
- CHAPTER 18 Cell Renewal and Cell Death 630
- CHAPTER 19 Cancer 660



# Contents

## PART 1 Fundamentals and Foundations 1

### 1 Introduction to Cells and Cell Research 1

#### 1.1 The Origin and Evolution of Cells 2

- How did the first cell arise? 2
- The evolution of metabolism 4
- Prokaryotes 5
- Eukaryotic cells 6
- The origin of eukaryotes 8
- The development of multicellular organisms 10

#### 1.2 Experimental Models in Cell Biology 14

- E. coli* 15
- Yeasts 15
- Caenorhabditis elegans* and *Drosophila melanogaster* 16
- Arabidopsis thaliana* 17
- Vertebrates 18
- Animal cell culture 19

**Key Experiment** HeLa Cells: The First Human Cell Line 21

Viruses 21

**Molecular Medicine** Viruses and Cancer 22

#### 1.3 Tools of Cell Biology: Microscopy and Subcellular Fractionation 24

- Light microscopy 24
- Fluorescence microscopy 27
- Sharpening the focus and seeing cells deeper within living tissue 29
- Super-resolution microscopy: Breaking the diffraction barrier 31
- Electron microscopy 32
- Subcellular fractionation 34

DATA ANALYSIS PROBLEM 37

SUGGESTED READING 38

---

## 2 Physical Principles Underlying Cell Structure and Function 40

#### 2.1 Chemical Bonds, Thermodynamics, and ATP 40

- Atoms and molecules interact through chemical bonds 41
- The laws of thermodynamics and free energy changes govern chemical reactions 44
- Cells use ATP as an energy source to drive energetically unfavorable reactions 45

#### 2.2 Organic Molecules of Cells 48

- Carbohydrates 49
- Lipids 51
- Nucleic acids 53
- Proteins 58
- Key Experiment** The Folding of Polypeptide Chains 63

## 2.3 Enzymes as Biological Catalysts 68

- The catalytic activity of enzymes 68
- Mechanisms of enzymatic catalysis 69
- Coenzymes 71
- Regulation of enzyme activity 73

## 2.4 Cell Membranes 75

- Membrane lipids 76
- Membrane proteins 77

**Key Experiment** The Structure of Cell Membranes 78

Transport across cell membranes 79

DATA ANALYSIS PROBLEM 82

SUGGESTED READING 83

---

# 3 Fundamentals of Molecular Biology 84

## 3.1 Heredity, Genes, and DNA 84

- Discoveries indicate genes and chromosomes contain the genetic material 85
- Identification of DNA as the genetic material 87
- Determination of DNA structure 89
- DNA structure explains DNA replication 90

## 3.2 Expression of Genetic Information 92

- The role of messenger RNA 93
- The genetic code 93
- A basic model of gene expression 95
- RNA viruses and reverse transcription 97
- Key Experiment** The DNA Provirus Hypothesis 98

## 3.3 Recombinant DNA Technology 100

- Restriction endonucleases 100
- Generating recombinant DNA molecules 101
- DNA sequencing 106
- Generating recombinant proteins from cloned genes 108

## 3.4 Techniques to Detect and Examine Nucleic Acids and Proteins 110

- Amplification of DNA by the polymerase chain reaction 110
- Nucleic acid hybridization 112
- Antibodies as probes for proteins 114
- Antibody-based techniques 115

## 3.5 Techniques to Study Gene Function in Eukaryotes 118

- Gene transfer in plants and animals 119
- Mutagenesis of cloned DNAs 122
- GFP-fusion proteins 124
- Introducing mutations into cellular genes 125
- Genome engineering by the CRISPR/Cas system 127
- Key Experiment** CRISPR-Cas9 as a Programmable Tool for Genome Editing 129
- Targeting mRNA 130

DATA ANALYSIS PROBLEM 133

SUGGESTED READING 134

# PART 2 The Flow of Genetic Information 135

## 4 Genes and Genomes 135

### 4.1 The Structure of Eukaryotic Genes 135

- Introns and exons 137
- Key Experiment** The Discovery of Introns 139
- Roles of introns 141

### 4.2 Noncoding Sequences 143

- Noncoding RNAs 143
- Key Experiment** The ENCODE Project 145
- Repetitive sequences 147
- Gene duplication and pseudogenes 150

**4.3 Chromosomes and Chromatin 152**

- Chromatin 153
- Centromeres 156
- Telomeres 158

DATA ANALYSIS PROBLEM 160

SUGGESTED READING 161

**5 Replication, Maintenance, and Rearrangements of Genomic DNA 162****5.1 DNA Replication 162**

- DNA polymerases 163
- The replication fork 164
- The fidelity of replication 170
- Origins and the initiation of replication 171
- Telomeres and telomerase: Maintaining the ends of chromosomes 176
- Key Experiment** Telomerase Is a Reverse Transcriptase 177

**5.2 DNA Repair 179**

- Direct reversal of DNA damage 180

Excision repair 181

Translesion DNA synthesis 185

**Molecular Medicine** Colon Cancer and DNA Repair 186

Repair of double-strand breaks 187

**5.3 DNA Rearrangements and Gene Amplification 191**

Antibody genes 191

Gene amplification 196

DATA ANALYSIS PROBLEM 198

SUGGESTED READING 198

**6 RNA Synthesis and Processing 199****6.1 Transcription in Bacteria 199**

- Bacterial RNA polymerase 200
- Bacterial promoters 200
- Elongation and termination 202

**6.2 Transcription in Eukaryotes 204**

- Eukaryotic RNA polymerases 204
- General transcription factors and transcription by RNA polymerase II 204
- Transcription by RNA polymerases I and III 208

**6.3 RNA Processing and Turnover 212**

- Processing of ribosomal and transfer RNAs 212

Processing of mRNA in eukaryotes 215

Splicing mechanisms 217

**Key Experiment** The Discovery of snRNPs 220

Alternative splicing 222

**Molecular Medicine** Splicing Therapy for Duchenne Muscular Dystrophy 224

RNA editing 225

RNA degradation 226

DATA ANALYSIS PROBLEM 227

SUGGESTED READING 229

**7 Transcriptional Regulation and Epigenetics 230****7.1 Gene Regulation in *E. coli* 230**

- The *lac* operon: The prototype for transcriptional regulation 230
- The *lac* repressor: A prototype for negative control of transcription 231
- Catabolite activator protein: A prototype for positive control of transcription 233

Concurrent mechanisms link transcription to multiple parameters 234

**7.2 Transcription Factors in Eukaryotes 235***cis*-acting regulatory sequences: Promoters and enhancers 236

## x Contents

Transcription factor binding sites 240  
Transcription factors 243  
**Key Experiment** Isolation of a Eukaryotic  
Transcription Factor 244  
Regulation of elongation 246

### 7.3 Chromatin and Epigenetics 248

Histone modifications 249

**Key Experiment** The Role of Histone  
Modification 251  
Chromatin remodeling factors 254  
Histones and epigenetic inheritance 255  
DNA methylation 256  
Noncoding RNAs 258

SUGGESTED READING 260

DATA ANALYSIS PROBLEM 261

---

## 8 Protein Synthesis, Processing, and Regulation 263

### 8.1 Translation of mRNA 263

Transfer RNAs 264  
The ribosome 264  
The organization of mRNAs and the initiation  
of translation 267  
The process of translation 269  
Regulation of translation 273

### 8.2 Protein Folding and Processing 278

Chaperones and protein folding 278  
Protein misfolding diseases 281  
Enzymes that catalyze protein folding 283  
**Molecular Medicine** Alzheimer's  
Disease 283

Protein cleavage 285  
Attachment of carbohydrates and lipids 286

### 8.3 Regulation of Protein Function and Stability 288

Regulation by small molecules 289  
Protein phosphorylation and other  
modifications 290  
**Key Experiment** The Discovery of  
Tyrosine Kinases 294  
Protein–protein interactions 295  
Protein degradation 297  
Cascades of protein regulation 299

DATA ANALYSIS PROBLEM 301

SUGGESTED READING 303

---

## 9 Genomics, Proteomics, and Systems Biology 304

### 9.1 Genomics and Transcriptomics 304

The human genome 305  
**Key Experiment** The Human Genome 306  
The genomes of other vertebrates 308  
Next-generation sequencing and  
personal genomes 310  
Global analysis of gene expression 314

### 9.2 Proteomics 316

Identification of cell proteins 317  
Global analysis of protein localization 318  
Protein interactions 319

### 9.3 Systems Biology 323

Systematic screens of gene function 324  
Regulation of gene expression 325  
Networks 326  
Synthetic biology 328  
**Molecular Medicine** COVID-19 and  
Synthetic Biology 331

DATA ANALYSIS PROBLEM 333

SUGGESTED READING 335

## **PART 3 Subcellular Structures and Functions 336**

### **10 The Nucleus 336**

#### **10.1 The Nuclear Envelope and Traffic between the Nucleus and the Cytoplasm 336**

Structure of the nuclear envelope 336

**Molecular Medicine** Nuclear Lamina Diseases 340

The nuclear pore complex 340

Selective transport of proteins to and from the nucleus 343

**Key Experiment** Identification of Nuclear Localization Signals 344

Transport of RNAs 348

Regulation of nuclear protein import 349

#### **10.2 The Organization of Chromatin 350**

Chromosome territories 351

Chromatin localization and transcriptional activity 352

Replication factories and transcription hubs 355

#### **10.3 Nuclear Bodies 356**

The nucleolus and rRNA 357

Polycomb bodies: Centers of transcriptional repression 360

Cajal bodies and nuclear speckles: Processing and storage of snRNPs 360

**DATA ANALYSIS PROBLEM 362**

**SUGGESTED READING 364**

---

### **11 Protein Processing and Sorting: The Endoplasmic Reticulum, Golgi Apparatus, and Lysosomes 365**

#### **11.1 The Endoplasmic Reticulum 366**

The rough endoplasmic reticulum and protein secretion 366

Targeting proteins to the rough endoplasmic reticulum 368

**Key Experiment** The Signal Hypothesis 369

Insertion of transmembrane proteins into the rough ER membrane 373

Protein folding and processing in the rough ER 379

Quality control in the rough ER 381

The smooth ER and lipid synthesis 385

Export of proteins and lipids from the ER 386

#### **11.2 The Golgi Apparatus 389**

Organization of the Golgi 389

Protein glycosylation within the Golgi 390

Lipid and polysaccharide metabolism in the Golgi 392

Protein sorting and export from the Golgi apparatus 393

#### **11.3 The Mechanism of Vesicular Transport 396**

Assembly of vesicle coat proteins drives vesicle budding 398

GTP-binding proteins coordinate vesicle budding and cargo recruitment 400

Tethering factors and SNAREs mediate vesicle docking and fusion 401

#### **11.4 Lysosomes 402**

Acid hydrolases: The degradative enzymes of lysosomes 403

**Molecular Medicine** Gaucher Disease 403

Lysosome formation is coupled to endocytosis 404

Autophagy is a critical function of lysosomes 404

**DATA ANALYSIS PROBLEM 409**

**SUGGESTED READING 410**

## 12 Mitochondria, Chloroplasts, and Peroxisomes 411

### 12.1 Mitochondrial Structure, Composition, and Dynamics 411

- Structure and composition of mitochondria 412
- Mitochondrial dynamics 414

### 12.2 Oxidative Catabolism of Glucose and Fatty Acids 417

- Glycolysis 417
- The citric acid cycle 419
- Fatty acid oxidation 421

### 12.3 Oxidative Phosphorylation 422

- Overview of oxidative phosphorylation through chemiosmotic coupling 422
- Key Experiment** The Chemiosmotic Theory 424
- Mechanisms of the electron transport chain 425
- Coupling of proton flow to ATP production by ATP synthase 427

### 12.4 Mitochondrial Assembly and Maintenance 429

- The genetic system of mitochondria 430
- Molecular Medicine** Mitochondrial Replacement Therapy 431
- Import of nuclear-encoded mitochondrial proteins 432
- Mitochondrial lipids 436
- Transport of metabolites across the inner membrane 436

### 12.5 Chloroplasts and Other Plastids 438

- Chloroplast structure and composition 439
- Photosynthesis 442
- The chloroplast genome 446
- Import and sorting of chloroplast proteins 446
- Other plastids 449

### 12.6 Peroxisomes 451

- Functions of peroxisomes 452
- Peroxisome assembly 453

### DATA ANALYSIS PROBLEM 456

### SUGGESTED READING 457

---

## 13 The Cytoskeleton and Cell Movement 458

### 13.1 Structure and Organization of Actin Filaments 458

- Assembly and organization of actin filaments 459
- Association of actin filaments with the plasma membrane 462
- Microvilli 465
- Cell surface protrusions and cell movement 466

### 13.2 Myosin Motors 469

- Muscle contraction 469
- Contractile assemblies of actin and myosin in nonmuscle cells 473
- Unconventional myosins 474

### 13.3 Microtubules 476

- Structure and dynamic organization of microtubules 476
- Assembly of microtubules 480
- MAPs and the organization of microtubules 481

### 13.4 Microtubule Motors and Movement 483

- Microtubule motor proteins 483
- Key Experiment** The Isolation of Kinesin 484
- Cargo transport and intracellular organization 486
- Cilia and flagella 487
- Microtubules during mitosis 490

**13.5 Intermediate Filaments 492**

- Intermediate filament proteins 493
- Assembly of intermediate filaments 494
- Intracellular organization of intermediate filaments 495

**Key Experiment** Function of Intermediate Filaments 497

**DATA ANALYSIS PROBLEM 499**

**SUGGESTED READING 501**

**14 The Plasma Membrane 502****14.1 Structure of the Plasma Membrane 502**

- The lipid bilayer 502
- Plasma membrane proteins 506
- Plasma membrane domains 510

**14.2 Transport of Small Molecules 513**

- Facilitated diffusion and carrier proteins 514
- Ion channels 514
- Active transport driven by ATP hydrolysis 525

Active transport driven by ion gradients 528

**Molecular Medicine** Cystic Fibrosis 529

**14.3 Internalization of Large Molecules by Endocytosis 531**

- Phagocytosis 532
- Clathrin-mediated endocytosis 533
- Key Experiment** The LDL Receptor 535

**DATA ANALYSIS PROBLEM 539**

**SUGGESTED READING 541**

**15 Cell Walls, the Extracellular Matrix, and Cell Interactions 542****15.1 Cell Walls 542**

- Bacterial cell walls 542
- Eukaryotic cell walls 543

**15.2 The Extracellular Matrix and Cell–Matrix Interactions 546**

- Matrix structural proteins 546
- Matrix polysaccharides 548
- Adhesion proteins 550
- Cell–matrix interactions 551
- Key Experiment** The Characterization of Integrin 551

**15.3 Cell–Cell Interactions 554**

- Adhesion junctions 554
- Tight junctions 556
- Gap junctions 557
- Molecular Medicine** Gap Junction Diseases 558
- Plasmodesmata 559
- Tunneling nanotubes 560

**DATA ANALYSIS PROBLEM 561**

**SUGGESTED READING 562**

**PART 4 Cell Regulation 563****16 Cell Signaling 563****16.1 Signaling Molecules and Their Receptors 563**

- Modes of cell–cell signaling 564
- Steroid hormones and the nuclear receptor superfamily 565

- Signaling by other small molecules 567
- Peptide hormones and growth factors 568

**16.2 G Proteins and Cyclic AMP 570**

- G proteins and G protein-coupled receptors 570

**Key Experiment** G Protein-Coupled Receptors and Odor Detection 571

The cAMP pathway: Second messengers and protein phosphorylation 574

### 16.3 Tyrosine Kinases and Signaling by the MAP Kinase and PI 3-Kinase Pathways 577

Receptor tyrosine kinases 578

Nonreceptor tyrosine kinases 579

MAP kinase pathways 582

**Molecular Medicine** Cancer: Signal Transduction and the *ras* Oncogenes 583

The PI 3-kinase/Akt and mTOR pathways 586

### 16.4 Receptors Coupled to Transcription Factors 591

The TGF- $\beta$ /Smad pathway 591

NF- $\kappa$ B signaling 591

The Wnt and Notch pathways 592

### 16.5 Signaling Dynamics and Networks 594

Feedback loops and signaling dynamics 594

Networks and crosstalk 595

DATA ANALYSIS PROBLEM 596

SUGGESTED READING 597

---

## 17 The Cell Cycle 598

### 17.1 The Eukaryotic Cell Cycle 598

The cell cycle consists of four sequential phases 599

Extracellular signals and cell growth regulate progression through the cell cycle 600

Cell cycle checkpoints 602

### 17.2 Regulators of Cell Cycle Progression 604

Cdk1 and cyclin B: The prototype regulators of cell cycle progression 604

**Key Experiment** The Discovery of MPF 605

**Key Experiment** The Identification of Cyclin 607

Families of cyclins and cyclin-dependent kinases 609

Growth factors and the regulation of G<sub>1</sub> Cdks 610

S phase and regulation of DNA replication 612

DNA damage checkpoints 615

### 17.3 The Events of M Phase 617

Stages of mitosis 617

Mitotic kinases drive entry into mitosis 619

The spindle assembly checkpoint controls the metaphase-to-anaphase transition and exit from mitosis 623

Cytokinesis 625

DATA ANALYSIS PROBLEM 627

SUGGESTED READING 629

---

## 18 Cell Renewal and Cell Death 630

### 18.1 Stem Cells and the Maintenance of Adult Tissues 630

Proliferation of differentiated cells 631

Stem cells 632

Medical applications of adult stem cells 637

### 18.2 Pluripotent Stem Cells, Cellular Reprogramming, and Regenerative Medicine 639

Embryonic stem cells 639

**Key Experiment** Culture of Embryonic Stem Cells 641

Somatic cell nuclear transfer 642

Induced pluripotent stem cells 643

Transdifferentiation of somatic cells 645

### 18.3 Programmed Cell Death 647

The hallmarks of apoptosis 647

Caspases: The executioners of apoptosis 649

- Key Experiment** Identification of Genes Required for Programmed Cell Death 650
- Central regulators of apoptosis:
  - The Bcl-2 family 651
- Signaling pathways that regulate apoptosis 653
- Alternative pathways of programmed cell death 656
- DATA ANALYSIS PROBLEM** 657
- SUGGESTED READING** 659

## 19 Cancer 660

### 19.1 The Development and Causes of Cancer 660

- Types of cancer 660
- The development of cancer 661
- Properties of cancer cells 662
- Causes of cancer 665

### 19.2 Oncogenes 667

- Retroviral oncogenes 668
- Proto-oncogenes 669
- Key Experiment** The Discovery of Proto-Oncogenes 670
- Oncogenes in human cancer 671
- Functions of oncogene products 674

### 19.3 Tumor Suppressor Genes 679

- Identification of tumor suppressor genes 680
- Functions of tumor suppressor gene products 683
- Cancer genomics 685

### 19.4 Molecular Approaches to Cancer Treatment 687

- Prevention and early detection 687
- Oncogene-targeted drugs 688
- Molecular Medicine** Imatinib: Cancer Treatment Targeted against the *bcr/abl* Oncogene 691
- Immunotherapy 692
- DATA ANALYSIS PROBLEM** 696
- SUGGESTED READING** 698

**Appendix** 699

**Answers** 701

**Glossary** 732

**References** 749

**Index** 753



## About the Authors



**Geoffrey M. Cooper** is a Professor of Biology Emeritus at Boston University. Receiving a Ph.D. in Biochemistry from the University of Miami in 1973, he pursued postdoctoral work with Howard Temin at the University of Wisconsin, where he developed gene transfer assays to characterize the proviral DNAs of Rous sarcoma virus and related retroviruses. He then joined the faculty of Dana-Farber Cancer Institute and Harvard Medical School in 1975, where he pioneered the discovery of oncogenes in human cancers. He moved to Boston University as Chair of Biology in 1998 and subsequently served as Associate Dean of the Faculty for Natural Sciences, as well as teaching undergraduate cell biology and continuing his research on the roles of oncogenes in the signaling pathways that regulate cell proliferation and programmed cell death. He has authored over 100 research papers and two textbooks on cancer, as well as a series of medical thrillers based on his academic career.



**Kenneth W. Adams** is an Associate Professor of Biology at Bridgewater State University. He earned a Ph.D. in Molecular Biology, Cell Biology, and Biochemistry from Boston University in 2006, where he investigated the role of Bcl-2 family members in the regulation of apoptosis downstream of PI 3-kinase signaling in the lab of co-author Geoffrey M. Cooper. His subsequent postdoctoral research was conducted with Bradley T. Hyman at Massachusetts General Hospital, where he investigated the mechanisms through which apolipoprotein E and its receptors affect susceptibility to Alzheimer's disease. He then joined the Undergraduate Neuroscience Program at Boston University as a postdoctoral faculty fellow and lecturer, during which his research focused on the transcriptional network that drives neuronal differentiation using PC12 cells as a model. In 2013, he joined the faculty of Bridgewater State University, where he initially continued his focus on the molecular mechanisms that mediate neuronal differentiation but has more recently returned to the Alzheimer's work he conducted during his postdoctoral research. In 2016, Kenneth was awarded the Presidential Award for Distinguished Teaching at Bridgewater State University, where he also serves as the Director of Undergraduate Research.



# Preface

Cell biology is a vast and rapidly progressing field in which discoveries are made at a staggering pace, continuously expanding our understanding of the molecular events that govern cell behavior in physiology as well as cell misbehavior in disease. Likewise, the tools and techniques through which such discoveries are made steadily advance, enabling experimental approaches with ever increasing sophistication. For college-level educators, this raises several pedagogical questions, including: *How can we best guide students toward an understanding of cell biology that aligns with the contemporary field? How do we avoid overwhelming students with never-ending details when many such details are necessary to understand **how** and **why** cells work instead of rote memorizing **that** cells work? And how can we help students to integrate the product of science—knowledge—with the practice of science—experimentation and data interpretation?* Put another way, cell biology instructors face the challenge of cultivating both the foundational knowledge and analytical skills that students need for their entry into an increasingly complex field. From its First Edition to this Ninth, *The Cell: A Molecular Approach* has been designed to serve as a guide to meet that challenge.

## Organization

The book is divided into four parts. **Part I: Fundamentals and Foundations** summarizes how cells evolved and describes basic model systems and techniques—microscopy and cell fractionation—used throughout cell research. The physical and chemical principles underlying cell structure and function are described, including chemical bonds, the laws of thermodynamics, the ubiquitous role of ATP as an energy source, and the major classes of molecules that make up cells. The key experiments that identified DNA as the hereditary material are reviewed, followed by discussion of discoveries through which the basic factors and steps of gene expression were elucidated. Part I concludes with analysis of essential tools—recombinant DNA and antibodies—that launched research into the molecular mechanisms described throughout Parts II, III, and IV.

**Part II: The Flow of Genetic Information** focuses on the molecular biology of cells and begins by dissecting the types of DNA sequences that make up genomes of diverse organisms and the mechanisms through which genomes are replicated and repaired when damaged. The molecular mechanisms of transcription and RNA processing are then discussed, followed by mechanisms of translation, protein processing, and protein regulation. Additional research tools and techniques that have been particularly critical to characterizing those mechanisms are integrated within the corresponding sections, and the last chapter in Part II introduces methodologies used for large-scale analyses.

**Part III: Subcellular Structures and Functions** includes chapters on the nucleus, cytoplasmic organelles, the cytoskeleton, the plasma membrane, and the extracellular matrix. This part of the book starts with coverage of the nucleus, which puts

the molecular biology of Part II within the context of the eukaryotic cell, and then works outward through cytoplasmic organelles and the cytoskeleton to the plasma membrane and the exterior of the cell. These chapters are relatively self-contained, however, and could be used in a different order should that be more appropriate for a particular course.

Finally, **Part IV: Cell Regulation** focuses on the exciting and fast-moving area of cell regulation, including coverage of topics such as cell signaling, the cell cycle, stem cells, and programmed cell death. This part of the book concludes with a chapter on cancer, which synthesizes the consequences of defects in basic cell regulatory mechanisms.

## New to this Edition

This Ninth Edition of *The Cell* is the result of a wholistic review of the previous edition. Not only has the content been updated to keep pace with key advances in the field but several additional changes have been incorporated, stemming from the following goals.

### Expedite Discussion of the Flow of Genetic Information

A major change in this edition relates to its overall organization. The mechanisms that mediate the flow of genetic information arguably represent the most fundamental basis for cellular life, which is reflected by *The Cell's* dedication of five chapters to this content: Genes and Genomes; Replication, Maintenance, and Repair of Genomic DNA; RNA Synthesis and Processing; Transcriptional Regulation and Epigenetics; and Protein Synthesis, Processing, and Regulation. For this Ninth Edition, Parts I and II have been reorganized to place those five chapters earlier in the table of contents. To do so, the content covered in the Eighth Edition's Chapter 3, Bioenergetics and Metabolism, has been dispersed across several chapters. Given the centrality of the laws of thermodynamics in all cellular events (including the flow of genetic information) and the ubiquitous role of ATP as an energy source to drive those events, these concepts have been combined with discussion of molecules and membranes in Chapter 2, which is newly titled Physical Principles Underlying Cell Structure and Function. Discussion of glycolysis, oxidative phosphorylation, and photosynthesis have been moved to Chapter 12: Mitochondria, Chloroplasts, and Peroxisomes. Additionally, Chapter 5 in the Eighth Edition—Genomics, Proteomics, and Systems Biology—now follows discussion of Protein Synthesis, Processing, and Regulation. Not only does this revision move the chapters related to the flow of genetic information earlier in the book, it also allows students to develop a stronger foundational knowledge of the concepts therein before applying them in the context of methodologies for large-scale analysis discussed in Genomics, Proteomics, and Systems Biology.

### Fill Gaps in Molecular Explanations

In 13 years of teaching Cell Biology, I have been continuously inspired by students' thirst for molecular explanations on **how** and **why** cellular events take place. From questions on how transcription by RNA polymerase II is terminated to why kinases exhibit substrate specificity to how importins pass through the selective barrier of the nuclear pore complex, students are seldom satisfied unless molecular explanations that go beyond rote memorization are provided. Indeed, the recognition that molecular explanations for all cellular events must exist, whether understood by the field or not, and the curiosity to seek out those explanations are essential characteristics of a cell biologist. Thus, an overarching goal while revising this Ninth Edition was to fill in gaps where molecular explanations were less apparent or have changed since the Eighth Edition. Examples of where such details were added include descriptions of transcription termination by RNA polymerase II

in Chapter 6, factors that mediate epigenetic inheritance of DNA methylation in Chapter 7, the roles of recognition motifs in kinase–substrate specificity in Chapter 8, and the characteristics of importins that enable their passage through the nuclear pore complex in Chapter 10.

To supplement updates to the text, several new figures are included—for example, Figure 6.9, which illustrates the key factors and events that cause transcription termination by RNA polymerase II, and Figure 8.32, which provides an example of elements that mediate kinase–substrate specificity. Existing figures were revised to incorporate molecular explanations for the events they depict—for example, Figure 7.26 was revised to include factors responsible for epigenetic inheritance of DNA methylation patterns and Figure 10.10 illustrates how importins interact with and penetrate the subunits that make up the selective barrier within the nuclear pore complex.

### **Incorporate Recent Discoveries and Advances**

A third goal in revising this edition was to incorporate key discoveries and concepts that have recently taken hold in the field. These include discussion of intrinsically disordered regions in protein structure in Chapter 2, their role in mediating liquid-liquid phase separation (LLPS) in Chapter 8, and the contributions of LLPS to formation of membraneless compartments (e.g., transcription hubs and the nucleolus in Chapter 10) and other molecular events (e.g., protein import into chloroplasts in Chapter 12). Updates on the ever-increasing list of noncoding RNAs (e.g., lncRNAs) expressed in eukaryotic organisms and their putative contributions to organismal complexity are added in the context of Chapter 4: Genes and Genomes and Chapter 9: Genomics, Proteomics, and Systems Biology and a more thorough analysis of the molecular machinery that mediates autophagy is provided in Chapter 11: Protein Processing and Sorting. Given the impact that CRISPR/Cas technology is having on research approaches, a new Key Experiment box in Chapter 3: Fundamentals of Molecular Biology describes the first demonstration by Jennifer Doudna and Emmanuelle Charpentier that bacterial CRISPR/Cas9 can be converted into an experimental tool for targeted genome modification. A new Molecular Medicine box is also added to Chapter 9, centered on the development of mRNA vaccines to combat the COVID-19 pandemic. The Molecular Medicine box on Alzheimer's Disease in Chapter 8: Protein Synthesis, Processing, and Regulation was also revised to include discussion of immunotherapy as an approach to treating the disease and the controversial approval of the first ever amyloid- $\beta$ -directed immunotherapy (Aducanumab) by the US Food and Drug Administration in 2021.

### **Develop the Data Analysis Problems**

A fourth goal of this edition was to re-envision the Data Analysis Problems that conclude each chapter to provide tools that help students integrate the product of science—knowledge—with the practice of science—experimentation and data interpretation. There are 16 new Data Analysis Problems; others have been significantly revised. Each of these new or updated Data Analysis Problems now include a brief background section to provide students a context within which to consider the experiments. While the Data Analysis Problems for Chapters 1–5 include data from a single experiment, those for Chapters 6–19 include data from multiple experiments, mimicking how research studies most often entail series of experiments that build on each other.

The top priority in selecting data for the Data Analysis Problems was that they relate to and reinforce concepts discussed in the corresponding chapter. For example, the new Data Analysis Problem for Chapter 10: The Nucleus investigates the nature of the selective barrier within the nuclear pore complex and how importins pass through that barrier. Opportunities to link content from the chapter to

disease also guided the selection of data. The Data Analysis Problem for Chapter 6: RNA Synthesis and Processing, for example, examines the potential contribution of TATA-binding protein to oncogenic transformation, the Data Analysis Problem for Chapter 13: The Cytoskeleton and Cell Movement examines the role of an actin-binding protein in metastasis, the Data Analysis Problem for Chapter 14: The Plasma Membrane evaluates whether receptor-mediated endocytosis may contribute to the spread of toxic tau proteins between neurons during Alzheimer's disease and other tauopathies, and the Data Analysis Problem for Chapter 18: Cell Renewal and Cell Death presents evidence that apoptosis induced through p53 and PUMA may contribute to neurodegeneration associated with amyotrophic lateral sclerosis and frontotemporal dementia.

Another priority in developing the Data Analysis Problems was to incorporate data from experimental techniques covered in the book and, in many cases, include multiple techniques to help students learn how different methods can complement each other to investigate an experimental question. For example, the new Data Analysis Problem for Chapter 7: Transcriptional Regulation and Epigenetics includes data from luciferase reporter assays, electrophoretic-mobility shift assays, and chromatin immunoprecipitation (all discussed in Chapter 7), whereas the Data Analysis Problem for Chapter 17: The Cell Cycle includes data from immunoblot, immunocytochemistry, and retroviral transduction (all discussed in Chapter 3: Fundamentals of Molecular Biology) as well as DNA content analysis by flow cytometry (discussed in Chapter 17). Whenever possible, data from recently published articles were selected, with many of the new Data Analysis Problems based on articles published since 2017.

To support students' understanding and analysis of the Data Analysis Problems, several figures from the Eighth Edition depicting research techniques have been revised to more thoroughly illustrate how they are conducted. Figures 3.18, 3.26, and 3.27 depict cDNA cloning, immunocytochemistry, and immunoblotting, respectively; Figure 7.5 depicts the use of reporter plasmids to identify *cis*-acting elements; and Figure 9.13 depicts yeast two-hybrid assays. Where appropriate, technique figures are cross-referenced to facilitate independent study of each Data Analysis Problem by students.

Another key resource added is interactive versions of each Data Analysis Problem (available online), which walk students through how each experiment was conducted to generate the data presented, using customized versions of the corresponding technique figures in the book. Overall, the goal is to provide a resource through which students can integrate and apply concepts from the book while simultaneously learning the intellectual process of scientific inquiry within the field of cell biology. Data Analysis Problems are available in Oxford Insight or via the enhanced e-book.

## Features

Several pedagogical features are incorporated into *The Cell* in order to help students master and integrate its contents. These features are reviewed below as a guide to students studying from this book.

### Chapter Organization

Each chapter is divided into three to five major sections, which are further divided into a similar number of subsections. An outline listing the major sections at the beginning of each chapter provides a brief overview of its contents. The major sections are numbered and self-contained to facilitate assignability.

## Learning Objectives

Each of the major sections begins with Learning Objectives, which help to organize and focus students' attention on the material.

## Summary and Questions

The major sections conclude with a review, including a section summary and questions (with answers in the back of the book). The questions span several levels of Bloom's taxonomy, ranging from knowledge and comprehension to analysis and synthesis.

## Marginal Notes

Major points are summarized as marginal notes throughout the text, providing a running outline of the material.

## Key Terms and Glossary

Key terms are identified as boldfaced words when they are introduced in each chapter and defined in the glossary at the end of the book.

## Illustrations and Micrographs

An illustration program of full-color art and micrographs has been carefully developed to complement and visually reinforce the text.

## Key Experiment and Molecular Medicine Essays

Each chapter contains either two Key Experiment essays or one Key Experiment and one Molecular Medicine essay. These features are designed to provide the student with a sense of both the experimental basis of cell and molecular biology and its applications to modern medicine. Additional questions are included in these essays, designed to focus attention on key aspects of the material. These essays are also a useful basis for student discussions, which can be accompanied with a review of the original paper upon which the experiments are based.

## Data Analysis Problem

Each chapter concludes with Data Analysis Problem that present data from original research papers, together with questions that engage students in the analysis of experimental methods and results (with answers in the back of the book). Like the Key Experiment and Molecular Medicine essays, the Data Analysis Problem provide excellent material for discussions and opportunities for student participation in active learning.

## FYIs

Each chapter contains sidebars that provide brief descriptive highlights of points of interest. The sidebars supplement the text and provide starting points for class discussion.

## References

Two key references for each major section are included at the end of each chapter. Comprehensive lists of references are provided as an online supplement.

---

**ACCESSIBLE COLOR CONTENT** Every opportunity has been taken to ensure that the content herein is fully accessible to those who have difficulty perceiving color. Exceptions are cases where the colors provided are expressly required because of the purpose of the illustration.

## Acknowledgements

It has been an absolute honor and privilege to take on revising *The Cell* for this Ninth Edition. Geoffrey M. Cooper's vision and masterful writing are what made this book the success it has been through eight editions and his review and feedback on all edits and updates in this edition were essential. I could not ask for a better mentor, colleague, friend, and now co-author.

Thank you, first and foremost Alexandra Zilz Adams—without your boundless support, never-ending encouragement, and invaluable insight, this Ninth Edition would not have been possible. My heartfelt thanks are also extended to Ulla Hansen, Bradley T. Hyman, Amy Friedman, Merideth Krevosky, Karen Kane, Barbara Ott, Steve James, Joe Birzes, Dave Bergey, and Joseph Carapucci—the impact of your wisdom, care, and influence is interwoven throughout this edition of *The Cell*. Sincerest thanks to colleagues listed below for reviewing early drafts of this edition and providing insightful feedback.

Allison Abbott	<i>Marquette University Biological Sciences Shorewood</i>
Meshak M. Afithile	<i>Western Illinois University</i>
James T. Arnone	<i>William Paterson University</i>
Uwe Beffert	<i>Boston University</i>
Wade Bell	<i>Virginia Military Institute</i>
Daniel Bergey	<i>Great Basin College</i>
Allan Blake	<i>Seton Hall University</i>
Erick Bourassa	<i>Mississippi College</i>
Jason Bush	<i>California State University, Fresno</i>
Christian Danve Castroverde	<i>Wilfrid Laurier University</i>
David Champlain	<i>University of Southern Maine</i>
Heather Cook	<i>Wagner College</i>
Jennifer Cooper	<i>Kennesaw State University</i>
Katie DeCicco-Skinner	<i>American University</i>
Janet Duert	<i>Ohio State University</i>
Kevin Edwards	<i>Illinois State University</i>
Eric Engstrom	<i>Monmouth College</i>
Karl Fath	<i>Queens College – City University of New York</i>
Laura Francis	<i>University of Massachusetts, Amherst</i>
Jennifer Freytag	<i>Russell Sage College</i>
Valerie Haywood	<i>Case Western Reserve University</i>
Lisa Kadlec	<i>Wilkes University</i>

Renuka Karunagoda	<i>Wilfrid Laurier University</i>
Janet Kirkley	<i>Knox College</i>
Quynh Chu LaGraff	<i>Union College</i>
Hyoung-gon Lee	<i>University of Texas at San Antonio</i>
Faith Liebl	<i>Southern Illinois University Edwardsville</i>
Nilanjan Lodh	<i>Marquette University</i>
Sukanya Lodh	<i>Marquette University</i>
Perpetua Muganda	<i>North Carolina A&amp;T State University</i>
Shanna Nifoussi	<i>University of Wisconsin-- Superior</i>
German Rosas-Acosta	<i>The University of Texas at El Paso</i>
Donald Rowen	<i>University of Nebraska</i>
Edmund Rucker	<i>University of Kentucky</i>
Michael Sacher	<i>Concordia University</i>
Steven Schwartzbach	<i>University of Memphis</i>
Tim Sherman	<i>University of South Alabama</i>
Michael Sikes	<i>North Carolina State University</i>
Kay Song	<i>Georgia State University</i>
Yewseok Suh	<i>High Point University</i>
Heather Thieringer	<i>Princeton University</i>
Catherine Trivigno	<i>Florida Atlantic University Wilkes Honors College</i>
Brian Tsukimura	<i>California State University, Fresno</i>
Ashok Upadhyaya	<i>University of South Florida</i>
Li Yao	<i>Wichita State University</i>

I am very grateful to have worked on this edition with Joan Kalkut, Senior Editor, whose support, guidance, and patience were extremely helpful throughout the writing, copy editing, and production process. Sincerest thanks also to an incredible production team that included Joan Gemme (Production Manager/Art Director), Johannah Walkowicz (Senior Production Editor), Richard Neilsen (Book Designer/Production Specialist), Meg Britton Clark (Book Designer/Production Specialist), Mark Siddall (Photo Research Editor), Wendy Walker (Copy Editor), Peter Lacey (Senior Content Development Editor), Olivia Clark (Media Editor), and Cailen Swain (Permissions Supervisor). Thanks also to Elizabeth Morales for her contribution to the beautiful art program. What a journey it has been, and I could not have asked to be part of a better team.

Kenneth W. Adams

# Digital Resources for

## *The Cell: A Molecular Approach*, NINTH EDITION

### Optimize Student Learning with Oxford Insight

*The Cell: A Molecular Approach*, Ninth Edition, is available in **Oxford Insight**. **Oxford Insight** delivers the trusted content of *The Cell* within a powerful, data-driven learning experience designed to increase student success. A guided and curated learning environment—delivered either via LMS/VLE integration or standalone—**Oxford Insight** provides access to the e-book, multimedia resources, assignable/gradable activities and exercises, and analytics on student achievement and progress. As students work through the course material, **Oxford Insight** automatically sets personalized learning paths for them, based on their specific performance.

Developed with applied social, motivational, and personalized learning research, **Oxford Insight** enables instructors to deliver an immersive experience that empowers students by actively engaging them with assigned reading. This approach, paired with real-time actionable data about student performance, helps instructors ensure that all students are best supported along their unique learning paths.

#### WITH OXFORD INSIGHT, INSTRUCTORS CAN:

- Assign auto-scored multiple-choice, fill-in, and other machine-gradable questions
- Score specific items (including open-ended questions) with feedback
- Export grades and change grading points
- Establish a course roster and add/drop students
- Share courses and resources with students and faculty
- Sync real-time assignments with LMS/VLE gradebooks
- Author new content and/or customize the publisher-provided content

For more information on how *The Cell: A Molecular Approach*, Ninth Edition, powered by **Oxford Insight**, can enrich the teaching and learning experience in your course, please visit [oxfordinsight.oup.com](http://oxfordinsight.oup.com) or contact your Oxford University Press representative.

#### CONTENTS INCLUDE:

- *Interactive Data Analysis Problems*: New to this edition, these interactive activities bring the book's Data Analysis Problems to life, presenting data from original research papers and asking students to analyze experimental methods and results. The Interactive Data Analysis Problems include three components:
  - *Research Techniques*: Visual overviews of research techniques discussed throughout *The Cell* that are relevant to each problem, with a quiz to test understanding

- *Experimental Questions*: Image walkthroughs of each Interactive Data Analysis Problem's experimental question and method, helping students envision the research process
- *Assessment*: Quizzes and short answer questions that encourage students synthesize what they have learned and apply that knowledge to new research

#### ANIMATIONS AND VIDEOS

- *Videos*: Informative and engaging videos help students understand complex cellular and molecular structures and processes
- *Animations*: Narrated animations of key concepts and processes

Both videos and animations are accompanied by assignable quizzes

#### SELF-STUDY AND PERSONALIZED PRACTICE

- *Chapter Overviews*: Brief introductions to each chapter's content
- *Micrographs*: Interactive micrographs illustrating cellular structure accompanied by practice assessments for student self-study
- *Additional Data Analysis Problems*: Additional research papers accompanied by free response practice questions challenge students to work with data
- *Self-Assessment Quizzes*: End-of-section questions to reinforce understanding of chapter material
- *Flashcards*: Study aids to help students learn the key terminology introduced in each chapter
- *Suggested Reading and Web Links*: A comprehensive list of additional print and online reference material for every chapter

#### ASSESSMENT

- *Chapter Quizzes*: Multiple-choice quizzes test comprehension of the chapter's key material, assignable by the instructor

For more information on how *The Cell: A Molecular Approach*, Ninth Edition, powered by **Oxford Insight**, can enrich the teaching and learning experience in your course, please visit [oxfordinsight.oup.com](http://oxfordinsight.oup.com) or contact your Oxford University Press representative.

## For the Instructor

(Available at [oup.com/he/cooper9e](http://oup.com/he/cooper9e))

Instructors using *The Cell*, Ninth Edition, have access to a wide variety of resources to aid in course planning, lecture development, and student assessment. Contents include the following:

#### Instructor's Manual:

- *Active Learning Guide* with in-class exercises, references to relevant media resources, clicker questions, and more, all structured around the in-text Learning Objectives and designed to help you create a dynamic learning environment in the classroom
- *Data Analysis Problems with answers* to challenge students by working with experimental data
- *Chapter overviews, reviews, and key terms*
- *Textbook Figures and Tables*: All available in PowerPoint slides

- *Animations and Videos*: A collection of *The Cell*'s animations and videos for use in lectures
- *Test Bank*: Revised and updated for the Ninth Edition, the Test Bank, which can be integrated directly into your learning management system, downloaded in Word Files, or downloaded as a Respondus package, includes more than 1,300 multiple-choice, fill-in-the-blank, true/false, and short-answer questions covering the full range of content in every chapter. All questions are referenced to Bloom's Taxonomy, making it easier to select the right balance of questions when building assessments.

## Enhanced E-book for the Student

(ISBN 9780197583913)

Ideal for self-study, *The Cell*, Ninth Edition, enhanced e-book delivers major components of the digital resources in a format independent from any courseware or learning management system platform, making its online resources more accessible for students.

The enhanced e-book is available via RedShelf, VitalSource, and other leading higher education e-book vendors and includes the following student resources:

- *Learning Objectives* outline the important takeaways of every major section.
- *Animations and Videos* help illustrate and bring to life concepts discussed in the text.
- *Interactive Data Analysis Problems* include image sequences of each problem's Research Techniques and Experimental Questions, bringing the experiments to life.
- Additional *Data Analysis Problems* are available for download and self-study.
- End-of-section *Review Questions* help students assess their own understanding.
- *Flashcards* help students master the hundreds of new terms introduced in the textbook.

# PART 1 Fundamentals and Foundations

## 1

## Introduction to Cells and Cell Research

Understanding the molecular biology of cells is one of the most active and fundamental areas of research in the biological sciences. This is true not only from the standpoint of basic science, but also with respect to numerous applications of cell and molecular biology to medicine, biotechnology, and agriculture. Especially with the ability to rapidly obtain sequences of complete genomes, progress in cell and molecular biology is opening new horizons in the practice of medicine. Striking examples include genome editing; the identification of genes that contribute to susceptibility to a variety of common diseases, such as Alzheimer's disease, heart disease, rheumatoid arthritis, and diabetes; the development of new drugs specifically targeted to interfere with the growth of cancer cells; designer drugs for treatment of cystic fibrosis; and the potential use of stem cells to replace damaged tissues and treat patients suffering from conditions like diabetes, Parkinson's disease, and spinal cord injuries.

Because cell and molecular biology is such a rapidly growing field of research, it is important to understand its experimental basis as well as the current state of our knowledge. This chapter will therefore focus on how cells are studied, as well as review some of their basic properties. Appreciating the similarities and differences between cells is particularly important to understanding cell biology. The first section of this chapter discusses both the unity and the diversity of present-day cells in terms of their evolution from a common ancestor. On the one hand, all cells share common fundamental properties that have been conserved throughout evolution. For example, all cells employ DNA as their genetic material, are surrounded by plasma membranes, and use the same basic mechanisms for energy metabolism. On the other hand, present-day cells have evolved a variety of different lifestyles. Many organisms, such as bacteria, amoebas, and yeasts, consist of single cells that are capable of independent self-replication. More complex organisms are composed of collections of cells that function in a coordinated manner, with different cells specialized to perform particular tasks. The human body, for example, is composed of more than 200 different kinds of cells, each specialized for distinct functions such as memory, sight, movement, and digestion. The diversity exhibited by the many different kinds of cells is striking; for example, consider the differences between bacteria and the cells of the human brain.

The fundamental similarities between different types of cells provide a unifying theme to cell biology, allowing the basic principles learned from experiments with one kind of cell to be extrapolated and generalized to other cell types. Several kinds of cells and organisms are widely used to study different aspects of cell and molecular biology; the second section of this chapter discusses some of the properties of these cells that make them particularly valuable as experimental models. Finally, it is important to recognize that progress in cell biology depends heavily on the availability of experimental tools that allow scientists to make new observations or conduct novel kinds of experiments. This introductory chapter therefore

**1.1** The Origin and Evolution of Cells

**1.2** Experimental Models in Cell Biology

**1.3** Tools of Cell Biology: Microscopy and Subcellular Fractionation

**Molecular Medicine**

Viruses and Cancer

**Key Experiment**

HeLa Cells: The First Human Cell Line

concludes with a discussion of some of the experimental approaches used to study cells, as well as a review of some of the major historical developments that have led to our current understanding of cell structure and function.

## 1.1 The Origin and Evolution of Cells

### LEARNING OBJECTIVES

- 1.1.1** Explain how the first cell originated.
- 1.1.2** Describe the major steps in evolution of metabolism.
- 1.1.3** Illustrate the structures of eukaryotic and prokaryotic cells.
- 1.1.4** Outline the evolution of eukaryotic cells and multicellular organisms.

Cells are divided into two main classes, prokaryotes and eukaryotes, initially defined by whether they contain a nucleus. Prokaryotic cells, such as bacteria, lack a membrane-bound nucleus and are generally smaller and simpler than eukaryotic cells, which include the highly specialized cells of multicellular organisms. In spite of these differences, the same basic molecular mechanisms govern the lives of both prokaryotes and eukaryotes, indicating that all present-day cells are descended from a single primordial ancestor. How did this first cell develop? And how did the complexity and diversity exhibited by present-day cells evolve?

### How did the first cell arise?

It appears that life first emerged at least 3.8 billion years ago, approximately 750 million years after Earth was formed. How life originated and how the first cell came into being are matters of speculation, since these events cannot be reproduced in the laboratory. Nonetheless, several types of experiments provide important evidence bearing on some steps of the process.

It was first suggested in the 1920s that simple organic molecules could form and spontaneously polymerize into macromolecules under the conditions thought to exist in primitive Earth's atmosphere. At the time life arose, the atmosphere of Earth is thought to have contained little or no free oxygen, instead consisting principally of CO<sub>2</sub> and N<sub>2</sub> in addition to smaller amounts of gases such as H<sub>2</sub>, H<sub>2</sub>S, and CO. Such an atmosphere provides reducing conditions in which organic molecules, given a source of energy such as sunlight or electrical discharge, can form spontaneously. The spontaneous formation of organic molecules was first demonstrated experimentally in the 1950s when Stanley Miller (then a graduate student) showed that the discharge of electric sparks into a mixture of H<sub>2</sub>, CH<sub>4</sub>, and NH<sub>3</sub>, in the presence of water, leads to the formation of a variety of organic molecules, including several amino acids (**FIGURE 1.1**). Although Miller's experiments did not precisely reproduce the conditions of primitive Earth, they clearly demonstrated the plausibility of the spontaneous synthesis of organic molecules, providing the basic materials from which the first living organisms arose.

The next step in evolution was the formation of macromolecules. The monomeric building blocks of macromolecules have been demonstrated to polymerize spontaneously under plausible prebiotic conditions. Heating dry mixtures of amino acids, for example, results in their polymerization to form polypeptides. But the critical characteristic of the macromolecule from which life evolved must have been the ability to replicate itself. Only a macromolecule capable of directing the synthesis of new copies of itself would have been capable of reproduction and further evolution.

Of the two major classes of informational macromolecules in present-day cells (nucleic acids and proteins), only the nucleic acids are capable of directing

Organic molecules formed spontaneously in primitive Earth's atmosphere.


RNA can catalyze its own replication.

**FIGURE 1.1 Spontaneous formation of organic molecules**


Experiments first conducted by Stanley Miller in the 1950s demonstrated that conditions similar to those of primitive Earth can give rise to several organic molecules that are critical to cellular life, including many amino acids.

their own self-replication. Nucleic acids can serve as templates for their own synthesis as a result of specific base pairing between complementary nucleotides (FIGURE 1.2). A critical step in understanding molecular evolution was thus reached in the early 1980s, when it was discovered in the laboratories of Sid Altman and Tom Cech that RNA is capable of catalyzing a number of chemical reactions, including the polymerization of nucleotides. Further studies have extended the known catalytic activities of RNA, including the description of RNA molecules that direct the synthesis of a new RNA strand from an RNA template. RNA is thus uniquely able to both serve as a template and to catalyze its own replication. Consequently, RNA is generally believed to have been the initial genetic system, and an early stage of chemical evolution is thought to have been based on self-replicating RNA molecules—a period of evolution known as the **RNA world**. Ordered interactions between RNA and amino acids then evolved into the present-day genetic code, and DNA eventually replaced RNA as the genetic material.


As discussed further in Chapter 3, all present-day cells use DNA as the genetic material and employ the same basic mechanisms for DNA replication and expression of the genetic information. **Genes** are the functional units of inheritance, corresponding to segments of DNA that encode proteins or RNA molecules. The nucleotide sequence of a gene is copied into RNA by a process called **transcription**. For



**All present-day cells use the same genetic mechanisms.**



**FIGURE 1.2 Self-replication of RNA** Complementary pairing between nucleotides (adenine [A] with uracil [U] and guanine [G] with cytosine [C]) allows one strand of RNA to serve as a template for the synthesis of a new strand with the complementary sequence.



**FIGURE 1.3 Enclosure of self-replicating RNA in a phospholipid membrane** The first cell is thought to have arisen by the enclosure of self-replicating RNA and associated molecules in a membrane composed of phospholipids. Each phospholipid molecule has two long hydrophobic tails attached to a hydrophilic head group. The hydrophobic tails are buried in the lipid bilayer; the hydrophilic heads are exposed to water on both sides of the membrane.

RNAs that encode proteins, their nucleotide sequence is then used to specify the order of amino acids in a protein by a process called **translation**.

The first cell is presumed to have arisen by the enclosure of self-replicating RNA in a membrane composed of **phospholipids** (FIGURE 1.3). As discussed in detail in the next chapter, phospholipids are the basic components of all present-day biological membranes, including the plasma membranes of both prokaryotic and eukaryotic cells. The key characteristic of the phospholipids that form membranes is that they are **amphipathic** molecules, meaning that one portion of the molecule is soluble in water and another portion is not. Phospholipids have long, water-insoluble (**hydrophobic**) hydrocarbon chains joined to water-soluble (**hydrophilic**) head groups that contain phosphate. When placed in water, phospholipids spontaneously aggregate into a bilayer with their phosphate-containing head groups on the outside in contact with water and their hydrocarbon tails in the interior in contact with each other. Such a phospholipid bilayer forms a stable barrier between two aqueous compartments—for example, separating the interior of the cell from its external environment.

The enclosure of self-replicating RNA and associated molecules in a phospholipid membrane would thus have maintained them as a unit, capable of self-reproduction and further evolution. RNA-directed protein synthesis may already have evolved by this time, in which case the first cell would have consisted of self-replicating RNA and its encoded proteins.

### The evolution of metabolism

Because cells originated in a sea of organic molecules, they were able to obtain food and energy directly from their environment. But such a situation is self-limiting, so cells needed to evolve their own mechanisms for generating energy and synthesizing the molecules necessary for their replication. The generation and controlled utilization of metabolic energy is central to all cell activities, and the principal pathways of energy metabolism (discussed in detail in Chapter 12) are highly conserved in present-day cells. All cells use **adenosine 5′-triphosphate (ATP)** as their source of metabolic energy to drive the synthesis of cell constituents and carry out other energy-requiring activities, such as movement (e.g., muscle contraction). The mechanisms used by cells to generate ATP are thought to have

- Mad2 protein, 624  
Malaria, 330  
Malate, 420*f*  
Malate dehydrogenase, 420*f*  
Malignant tumors, 661  
*See also* Cancer  
Maller, James, 608  
Malus domestica (Apple), 11*t*  
Mammalian cells  
characteristics of introns and exons, 140*t*  
characteristics of non-human genomes, 308–310  
DNA polymerases in DNA replication, 166*f*  
experimental models, 18–19  
range of genome sizes, 136*f*  
somatic cell nuclear transfer, 642–643  
Mammary epithelial cells, 642  
Mannose-6-phosphate, 391, 393, 394*f*, 403  
Mannose-6-phosphate receptor, 391, 394*f*, 405*f*  
Mannosidase, 382*f*, 383  
MAP kinase pathways, 582–586  
MAP kinase/ERK kinase (MEK), 327, 584*f*, 585, 595*f*, 675  
*See also* Ras/Raf/MEK/ERK pathway  
MAPs. *See* Microtubule-associated proteins  
Markert, Clement, 604, 605–606  
Marshall, Barry, 666  
Martin, Gail, 641  
Martin, Steve, 668  
Mass spectrometry, 317–318  
Massively parallel sequencing. *See* Next-generation sequencing  
Mastectomy, 688  
Masui, Yoshio, 604, 605–606  
Matrix. *See* Mitochondrial matrix  
Matrix metalloprotease family, 553  
Matrix processing peptidase (MPP), 433*f*, 434  
Matthaei, Heinrich, 95  
Maturation promoting factor (MPF)  
discovery of, 604, 605–606  
regulation of M phase transition, 619–620  
structure and regulation of, 608–609  
MCC proteins, 624  
McCarty, Maclyn, 88  
McCulloch, Ernest, 633  
McKnight, Steven, 244  
Mcl-1, 241, 654*f*, 655  
MCM hexamers, 612–613, 614*f*, 615  
MCM2-7 protein, 168, 174  
MDM2 oncogene, 685  
MDM2 ubiquitin ligase, 616  
MDR transporters, 528  
Mechanical stress hypothesis of laminopathies, 340  
Mechanotransduction hypothesis of laminopathies, 341  
Mediator protein complex  
definition and function as a preinitiation complex, 207–208  
DNA looping and, 238  
repressors, 245, 246*f*  
transcription hubs and, 355*f*, 356  
transcriptional activators and, 245
- Medicine  
Alzheimer's disease and, 283–284  
applications of adult stem cells, 637–638  
cancer and *ras* oncogenes, 583  
colon cancer and DNA repair, 186  
cystic fibrosis, 529  
drugs to block SARS-CoV-2 replication, 286  
embryonic stem cells and, 639, 640, 642  
gap junction diseases, 558  
Gaucher disease, 403–404  
induced pluripotent stem cells and, 643  
mitochondrial replacement therapy, 431–432  
nuclear lamina diseases, 340–341  
splicing therapy for Duchenne muscular dystrophy, 224  
synthetic biology and COVID-19 mRNA vaccines, 330, 331–332  
therapeutic cloning and, 643  
viruses and cancer, 22  
*See also* Cancer; Cancer treatment; Human diseases; Regenerative medicine  
Megakaryocytes, 634  
Meiosis  
formation of haploid gametes, 86  
frog oocytes and maturation promoting factor, 604, 605–606  
MEK. *See* MAP kinase/ERK kinase  
MEK oncogene protein, 689*t*, 692  
Mekinist (trametinib), 689*t*  
MEKK proteins, 586*f*  
Melanoma, 689*t*, 691–692  
Mello, Craig, 131  
Membrane depolarization  
in action potentials, 522, 523*f*  
defined, 519  
in neurotransmission, 519, 520, 521*f*  
Membrane fluidity, 76, 505  
Membrane hyperpolarization, 522, 523*f*  
Membrane lipids  
anchoring of membrane proteins, 79  
membrane fluidity and, 505  
overview and description of, 76–77  
plasmalogens, 452  
synthesis in the smooth ER, 385–386  
Membrane potential  
depolarization in action potentials, 522, 523*f*  
depolarization in neurotransmission, 519, 520, 521*f*  
hyperpolarization in action potentials, 522, 523*f*  
resting membrane potential, 517–518, 522, 523*f*  
Membrane proteins  
anchoring in membrane lipids, 79  
export from the endoplasmic reticulum to the Golgi apparatus, 386–387  
export from the Golgi apparatus, 393, 394–395  
fluid mosaic model of membrane structure, 77, 78, 79  
insertion into the rough ER membrane, 373–379  
transport proteins, 80  
types of, 79  
Membrane-anchored growth factors, 569  
Membranes. *See* Cell membrane; Nuclear membrane; Plasma membrane; specific cellular membranes  
Mendel, Gregor, 85–86  
Merckel cell carcinoma, 666*t*  
Meselson, Matthew, 91, 93  
Messenger ribonucleoprotein particles (mRNPs), 215  
Messenger RNA (mRNA)  
alternative splicing, 142, 222–223, 225  
basic model of gene expression, 96–97  
defined, 93  
degradation, 226–227  
export from the nucleus, 348  
formation of polypeptides and, 60, 61*f*  
functions of, 53  
gene duplication and retrogenes, 150–152  
genetic code, 93–95  
internal ribosome entry sites, 269, 271  
localization of, 274  
polycistronic and monocistronic mRNAs, 268  
primary RNA transcript, 137  
processing in eukaryotes, 215–217  
protein structure and, 61–62  
RNA editing, 225–226  
RNA interference and (*see* RNA interference)  
splicing (*see* RNA splicing)  
structure in eukaryotes and prokaryotes, 268  
synthesis by RNA polymerase II, 204–208, 209*f*  
targeting in gene inactivation, 130–131  
transcriptomics, 314–315, 316  
translation, 263–277 (*see also* Translation)  
Metabolism, evolution of, 4–5  
Metal ions, 71  
Metaphase  
chromatin condensation during, 155–156  
chromosomes in, 156*f*, 157  
metaphase-to-anaphase transition, 623–625  
overview, 617, 618*f*, 619  
Metaphase plate, 619, 625  
Metastasis, 661  
Methane, 2, 3*f*, 41  
Methionine  
genetic code, 95*f*  
initiation of mRNA translation and, 268  
methionyl tRNA, 269, 270  
structure and properties of, 59*f*, 60  
Methionyl tRNA, 269, 270, 271*f*, 272  
Methylation  
of DNA, 256–258, 259  
of histones, 252, 253  
of proteins, 294  
5-Methylcytosine, 258  
Methylguanosine, 214*f*  
7-Methylguanosine cap, 215*f*, 216, 268–269, 275

- Methyltransferases, 216
- Mfn1. *See* Mitofusin 1
- Microfilaments, 459  
*See also* Actin filaments
- MicroRNAs (miRNAs)  
activity as tumor suppressor genes and oncogenes, 685  
description of, 274–275  
detecting in the human genome, 307  
export from the nucleus, 348  
nested genes and, 141  
organismal complexity and, 307, 308*f*  
overview and description of, 144–145  
RNA degradation and, 227  
RNA interference and translational repression, 144, 258–259, 274–276  
RNA polymerases that transcribe the genes of, 204  
transcriptional regulation and, 258–259  
*miR-17-92*, 685  
*miR-34*, 685
- Microscopy  
electron microscopy, 32–33, 34*f*  
fluorescence microscopy, 27–32  
light microscopy methods, 24–27  
super-resolution microscopy, 31–32
- Microtubule depolymerizing enzymes, 486, 491
- Microtubule-associated proteins (MAPs), 479, 481–482
- Microtubule-organizing centers, 480, 490
- Microtubules  
assembly of, 480–481  
astral microtubules, 490, 491, 492, 623  
binding of intermediate filaments to, 497  
cancer treatments and, 478–479  
cargo transport and positioning of organelles, 486–487  
cilia and flagella, 487–490  
definition and functions of, 476  
interpolar microtubules, 490, 491–492, 623  
kinetochore microtubules, 490, 491, 623  
MAPs and microtubule organization, 481–482  
during mitosis, 490–492  
mitotic spindle and (*see* Mitotic spindle)  
motor proteins, 483–486  
overview, 458*f*  
plant cell expansion and, 545–546  
structure and dynamic organization of, 476–479  
*See also* Spindle microtubules
- Microvilli  
intestinal epithelial cells, 510, 511*f*  
structure and organization of, 465–466
- Middle lamella, 559, 560*f*
- Miller, Stanley, 2, 3*f*
- Mim1 protein, 435*f*, 436
- MINIFLUX, 31
- 10 element, 200–202
- 35 element, 200–202
- Mismatch repair, 184–185, 186
- Mitchell, Peter, 423–425
- Mitchison, Tim, 478, 490
- Mitochondria  
animal and plant cells, 7*f*  
apoptosis and, 652–653  
assembly and maintenance, 429–437  
ATP synthesis and, 46  
autophagy and, 407  
brown fat and, 427  
chaperones and protein transport, 279, 280*f*  
compared to chloroplasts in ATP production, 438, 440–441  
DNA polymerase  $\gamma$ , 163  
endosymbiosis and the origin of, 8, 9*f*; 10  
fusion and fission, 414–416  
import of nuclear-encoded proteins, 432–436  
inner membrane (*see* Inner mitochondrial membrane)  
intermembrane space (*see* Intermembrane space)  
matrix (*see* Mitochondrial matrix)  
mitochondrial lipids, 436  
organization in networks, 416  
outer membrane (*see* Outer mitochondrial membrane)  
overview and functions of, 8, 411  
overview of catabolic pathways for ATP synthesis, 411–412  
oxidative catabolism of fatty acids, 421  
oxidative catabolism of glucose, 417–421  
oxidative phosphorylation, 422–428, 422–429, 429*f*  
RNA polymerase in, 204  
secretory pathway and, 368  
structure and composition of, 412–414  
summary of oxidative metabolism in, 429*f*
- Mitochondrial Eve, 431
- Mitochondrial fission, 414–416
- Mitochondrial fusion, 414–416
- Mitochondrial genome  
characteristics of, 8, 430–431  
genetic code of, 431  
mitochondrial fusion and exchange of genetic material, 416  
mitochondrial replacement therapy, 431, 432  
mutations and mitochondrial diseases, 431–432  
size of, 430
- Mitochondrial matrix  
function and composition of, 412, 413*f*, 414  
oxidative decarboxylation of pyruvate, 419  
oxidative metabolism in mitochondria and, 429*f*  
in oxidative phosphorylation, 422–423, 425*f*, 426  
presequence-dependent import of nuclear-encoded proteins, 433–434  
presequence-independent import of nuclear-encoded proteins, 434–435  
proton flow and ATP production by ATP synthase, 427–428  
transport of small molecules into and out of, 436–437
- Mitochondrial replacement therapy, 431, 432
- Mitofusin 1 (Mfn1), 414, 415*f*, 416
- Mitogen-activated protein kinases (MAP kinases)  
defined, 582  
ERK MAP kinase pathway, 582–585  
other MAP kinase pathways, 585, 586*f*  
scaffold proteins, 585–586
- Mitophagy, 407
- Mitosis  
breakdown of the nuclear envelope and Golgi apparatus, 621, 622*f*  
centrosomes and the assembly of microtubules, 480  
chromatin condensation, 155–156, 620–621  
chromosomes in, 156*f*  
defined, 617  
exit from, 625  
formation of the mitotic spindle, 618, 622–623  
microtubules during, 490–492  
mitotic kinases and entry into, 619–623  
role of centromeres in, 156–157  
spindle assembly checkpoint and metaphase-to-anaphase transition, 623–625  
stages of, 617–619
- Mitotic B cyclins, 610
- Mitotic checkpoint complex (MCC) proteins, 624
- Mitotic kinases, 619–623, 625
- Mitotic spindle  
attachment of chromosomes to, 157  
attachment of microtubules to kinetochores, 618–619, 623  
chromosome movement during mitosis and, 491–492, 625  
defined, 490  
formation of, 490, 618, 622–623  
microtubules and, 480  
spindle assembly checkpoint, 623–625
- Mizutani, Satoshi, 99
- MLH protein, 185
- MLK protein, 586*f*
- MLKL protein, 656
- Model organisms. *See* Experimental models
- Moderna pharmaceutical company, 330, 331–332
- Moerner, William, 31
- Molecular biology  
central dogma of, 93  
gene expression and protein synthesis, 92–99  
gene function analyses, 118–131 (*see also* Gene function analyses)  
heredity, genes, and DNA, 84–91  
methods to detect and examine nucleic acids, 110–113  
overview, 84  
recombinant DNA technology, 100–109  
RNA viruses and reverse transcription, 97–99

- Molecular cloning  
 DNA sequencing and, 106–107  
 expression of recombinant proteins, 108–109  
 gene transfer and, 119–122  
 generation of recombinant DNA, 101–106  
 molecular clones, 103–105  
 mutagenesis of cloned DNAs, 122–124  
 production of GFP-fusion proteins, 124
- Molecular medicine. *See* Medicine
- Molecular motors, 469  
*See also* Motor proteins
- Molecules  
 chemical bonds and chemical reactions, 41–44  
 hydrophilic or hydrophobic molecules, 4, 43  
 introduction, 40  
 nonpolar molecules, 43, 44  
 origin of life and, 2–4  
 polar molecules, 41, 43, 44  
*See also* Organic molecules
- Moloney murine leukemia, 669*f*
- Monocistronic mRNAs, 268
- Monoclonal antibodies, 115, 693
- Monocytes, 13, 634*f*
- Monod, Jacques, 230, 231–232
- Monopartite nuclear localization signals, 345
- Monosaccharides, 49–50, 51
- Moore, Claire, 139–140
- Moore, Peter, 267
- Motile cilia, 488–490
- Motor neurons, 520, 521*f*
- Motor proteins (molecular motors)  
 cargo transport and positioning of organelles, 486–487  
 chromosome movement during mitosis and, 157, 491, 492, 625  
 cilia and flagella, 489  
 defined, 469  
 kinesins and dyneins, 483–486  
 myosin, 469–476 (*see also* Myosin)
- Mouse (*Mus musculus*)  
 an experimental model, 18–19, 308  
 antibody genes, 192  
 conservation of functional gene regulatory elements, 326*f*  
 embryonic stem cells and, 639, 640, 641  
 genome size, 11*t*, 310*f*  
 $\beta$ -globin gene and introns, 138  
 induced pluripotent stem cells, 643–645  
 L cells, 21  
 methods of inactivating genes in, 126–127  
 methods of producing transgenic mice, 121–122  
 noncoding RNAs and organismal complexity, 308*f*  
 protein-coding sequences versus long noncoding RNAs, 146*t*  
 vertebrate genome evolution and, 309*f*  
*in vivo* transdifferentiation and, 646  
*See also* Transgenic mice
- MPP. *See* Maturation promoting factor
- mRNA. *See* Messenger RNA
- mRNA exporter complex, 348
- mRNA vaccines, 331–332
- mRNPs. *See* Messenger ribonucleoprotein particles
- MSH protein, 185
- MTE elements, 205, 206*f*
- mTOR oncogene protein, 689*t*
- mTOR pathway, 588–590, 595, 654*f*, 655
- mTORC1 complex, 588, 589, 590
- mTORC2 protein kinase, 587, 588, 589*f*
- Mullis, Kary, 110
- Multicellular organisms, development of, 10–13
- Multiphoton microscopy, 30, 31*f*
- Multivalent interactions, 296–297
- Mus musculus. *See* Mouse
- Muscle cells  
 contraction, 469–473  
 functions, 13  
 gap junctions, 557, 559  
 intermediate filaments, 497
- Muscle contraction  
 mechanisms in, 469–473  
 neuromuscular junctions, 520, 521*f*
- Muscle fibers  
 caveolae, 512  
 neuromuscular junctions, 520, 521*f*  
 sarcomere structure and organization, 469–470  
 satellite cells, 636–637  
 sliding filament model of muscle contraction, 470–473
- Muscular dystrophy, 224, 340–341, 464
- Mutagenesis  
 of cloned DNA, 122–124  
 introducing mutations into cellular genes, 125–127  
 mutagenesis primers, 122, 123*f*
- Mutations  
 development of cancer and, 662  
 diversity of immunoglobulins and, 193, 194, 195–196  
 DMD gene and muscular dystrophy, 224  
 errors in DNA replication and, 170, 171  
 transposable elements and, 148
- MutK protein, 184*f*, 185
- MutL protein, 184*f*, 185, 186
- MutS protein, 184*f*, 185, 186
- myc* oncogenes, 673, 675
- Myc proteins, 675
- Mycobacterium tuberculosis*, 467*f*
- Mycoplasma, 136*f*
- Mycoplasma mycoides*, 330
- Myelin, 558
- Myeloids, 634*f*
- Myelomas, 369, 695
- MyoD transcription factor, 645
- Myofibrils, 469–470
- Myoglobin, 63, 64–65
- Myosin light-chain kinase, 474, 475*f*
- Myosins  
 contractile assemblies in nonmuscle cells and, 473–474  
 contractile ring and, 625  
 microvilli and, 466  
 a molecular motor, 469  
 muscle contraction and, 469–473  
 unconventional myosins, 474–476  
 myosin I, 466, 475  
 myosin II, 471–472, 473–474  
 myosin V, 475–476  
 myosin VI, 466, 475, 476
- Myristic acid, 79, 287*f*, 509
- N*-Myristoylation, 287
- N**
- Na<sup>+</sup>-Ca<sup>2+</sup> transporter, 530
- NADH dehydrogenase (complex I), 425, 428, 431–432
- NADP reductase, 441, 443, 446
- NADs. *See* Nucleolus-associated domains
- Na<sup>+</sup>-H<sup>+</sup> transporter, 530
- Na<sup>+</sup>-K<sup>+</sup> pump (Na<sup>+</sup>-K<sup>+</sup> ATPase), 525–527, 529
- Nango, 643
- Nasopharyngeal carcinoma, 666*t*
- N-cadherin, 556
- NCAMs. *See* Neural cell adhesion molecules
- Neanderthal genome, 309*f*, 310
- Nebulin, 472
- Neck cancers, 689
- Necroptosis, 656
- Necrosis, 647–648
- Negative elongation factor (NELF), 246, 247*f*
- Negative staining, 33
- NELF. *See* Negative elongation factor
- Nematodes. *See* *Caenorhabditis elegans*
- Nernst equation, 518
- Nerve cells, organization of microtubules in, 481–482
- Nerve growth factor (NGF), 568, 578, 595, 654
- Nervous system, RNA editing and, 225–226
- Nervous tissue, 13
- Nested genes, 141
- Nestin, 493–494
- Networks  
 analysis of, 326–328  
 defined, 327  
 mitochondrial, 416  
 signaling networks, 595  
*See also* Actin networks
- Neural cadherin, 556
- Neural cell adhesion molecules (NCAMs), 555
- Neuroblastomas, 673
- Neurodegenerative diseases  
 associated with protein aggregation, 281–284  
 autophagy and, 408  
 liquid–liquid phase separation of proteins and, 296*f*, 297  
 nucleocytoplasmic transport and, 343  
 tunneling nanotubes and, 560  
*in vivo* transdifferentiation and, 646
- Neurofibrillary tangles, 283, 481  
*See also* Tau protein

- Neurofilament (NF) proteins, 493, 497  
 Neuromuscular junctions, 520, 521*f*  
 Neurons  
   defined, 13  
   as experimental models, 18  
   intermediate filament proteins, 493  
   intermediate filaments, 497  
   ion channels in neurotransmission and action potentials, 516–522, 523*f*  
   programmed cell death and, 654  
 Neuropeptides, 568, 569  
*Neurospora crassa*, 92  
 Neurotransmission  
   at neuromuscular junctions, 520, 521*f*  
   between neurons, 519–520  
   overview of, 516, 517*f*  
   resting membrane potential and, 517–518  
 Neurotransmitter receptors, 568  
 Neurotransmitters  
   mechanisms of action, 568  
   in neurotransmission, 516, 517*f*, 519, 520  
   nitric oxide signaling and, 567–568  
   paracrine signaling and, 564  
 Neutrophils, 532, 634*f*  
 Nexin, 489, 490  
 Next-generation sequencing, 107, 310–314  
 NF proteins. *See* Neurofilament proteins  
 NF- $\kappa$ B signaling, 591–592, 594–595  
 NF- $\kappa$ B transcription factor family, 349, 591–592, 594–595, 654*f*, 655  
 NGF. *See* Nerve growth factor  
 NHEJ. *See* Non-homologous end joining  
 Niacin, 73*t*  
 Nicastrin, 592, 593*f*  
 Niches, 637  
 Nickel compounds, 666  
 Nicolson, Garth, 77, 78, 506, 507  
 Nicotinamide adenine dinucleotide (NAD<sup>+</sup>/NADH<sub>2</sub>)  
   electron carrier in oxidation–reduction reactions, 72  
   electron transport chain and, 425, 426–427  
   fatty acid oxidation, 421  
   overview of catabolic pathways for ATP synthesis, 411–412  
   oxidative catabolism of glucose, 417, 418*f*, 419, 420, 421  
   oxidative decarboxylation of pyruvate, 419  
   oxidative metabolism in mitochondria and, 429*f*  
   oxidative phosphorylation and ATP synthesis, 417, 419, 421, 422, 423*f*, 428  
   related vitamin, 73*t*  
 Nicotinamide adenine dinucleotide phosphate (NADP<sup>+</sup>/NADPH)  
   dark reactions of photosynthesis, 438, 444, 445  
   light reactions of photosynthesis, 438, 441, 443, 444  
   related vitamin, 73*t*  
   synthesis of fatty acids, 51  
 Nicotinic acetylcholine receptors, 522, 524*f*  
 Nidogen, 551  
 Niedrgerke, Ralph, 470  
 Nirenberg, Marshall, 95  
 Nirmatrelvir, 286  
 Nitric oxide (NO), 567–568  
 Nitrogen, 43, 91  
 Nitroglycerin, 568  
 Nitrosylation, 294  
 Nivolumab (Opdivo), 694  
 N-linked glycoproteins, 286  
 N-linked glycosylation, 380  
 N-linked oligosaccharides, 382, 383, 390–391  
*Nocardia oitidis-caviarum*, 101*t*  
 Noller, Harry, 267  
 Nomura, Masayasu, 266  
 Non polar amino acids, 78  
 Noncoding RNAs  
   activity as tumor suppressor genes and oncogenes, 685  
   analysis of protein-RNA interactions, 321–322  
   ENCODE project and the identification of, 143–144, 145  
   human genome, 305, 307  
   long noncoding RNAs, 146 (*see also* Long noncoding RNAs)  
   microRNAs, 144–145 (*see also* MicroRNAs)  
   nested genes and, 141  
   nucleocytoplasmic transport, 348–349  
   organismal complexity and, 307, 308*f*  
   transcriptional regulation, 258–260  
 Noncoding sequences  
   gene duplication and pseudogenes, 150–152  
   introns, 137 (*see also* Introns)  
   noncoding RNAs, 143–146  
   overview, 143  
   repetitive sequences, 147–149  
 Noncompetitive inhibition, 73  
 Non-homologous end joining (NHEJ)  
   class switch recombination and, 196  
   CRISPR/Cas system and, 127, 128, 129  
   definition and description of, 187, 188*f*  
   V(D)J recombination and, 194  
 Non-human primate genomes, 309–310  
 Non-neurodegenerative localized diseases, 281*t*  
 Nonpolar amino acids, 59–60  
 Nonpolar covalent bonds, 41  
 Nonpolar molecules, 43, 44  
 Nonreceptor tyrosine kinases, 578, 579–581, 675  
 Non-sex-linked Emery–Dreifuss muscular dystrophy, 340  
 Nonstandard base pairing, 264, 265*f*  
 Non-virus-induced cancer hypothesis, 670  
 Northern blotting, 113  
 Notch pathway, 592–593, 637  
 Notch protein, 592–593  
*NotI* endonuclease, 101*t*  
 Noxa protein, 653, 684  
 NTF2 protein, 346  
 Nuclear bodies  
   biomolecular condensates, 297  
   Cajal bodies, 360–362  
   nucleolus, 357–360 (*see also* Nucleolus)  
   overview and examples of, 357  
   Polycomb bodies, 357*t*, 360, 361*f*  
 Nuclear division. *See* Mitosis  
 Nuclear envelope  
   breakdown during mitosis, 621, 622*f*  
   laminopathies, 340–341  
   nuclear pore complexes, 340–343  
   overview, 336  
   pathway of transmembrane proteins to, 379  
   secretory pathway and, 367, 368*f*  
   selective transport of proteins, 343–348  
   structure and function, 336–340  
   transport of RNAs, 348–349  
 Nuclear export signals, 346–348  
 Nuclear lamina  
   breakdown during mitosis, 621, 622*f*  
   definition and description of, 338–340  
   inner nuclear membrane and, 337  
   lamina-associated domains, 354  
   laminopathies, 340–341  
 Nuclear lamins  
   apoptosis and, 651  
   Charcot-Marie-Tooth disease and, 558  
   phosphorylation of, 495  
   size and site of expression, 493*t*, 494  
 Nuclear localization signals, 343–345, 349  
 Nuclear membrane  
   nuclear pore complexes and, 342  
   secretory pathway and, 368*f*  
   structure and function, 336–337  
   *See also* Inner nuclear membrane  
 Nuclear pore complexes  
   breakdown during mitosis, 621, 622*f*  
   mechanisms of transport through, 341*f*  
   (*see also* Nucleocytoplasmic transport)  
   neurodegenerative diseases and, 343  
   nuclear membrane and, 337*f*, 338  
   structure and function, 340–343  
 Nuclear receptor superfamily, 565–566, 567*f*  
 Nuclear speckles, 357*t*, 362  
 Nuclear transport receptors, 343  
 Nucleic acid hybridization, 112–113  
 Nucleic acid probes, 27  
 Nucleic acids  
   antisense nucleic acids, 130, 131*f*  
   gel electrophoresis, 101, 102*f*  
   methods to detect and examine, 110–113  
   origin of life and characteristics of, 2–4  
   replication of, 57  
   structure and function, 53–57, 58*f*  
   *See also* Deoxyribonucleic acid; Ribonucleic acid  
 Nucleocytoplasmic transport  
   importins and RAN protein, 345–346  
   neurodegenerative diseases and, 343  
   nuclear export signals and exportin, 346–348  
   nuclear localization signals, 343–345  
   nuclear transport receptors, 343  
   overview of mechanisms through nuclear pore complexes, 341  
   regulation of protein import, 349–350  
   selective transport of proteins, 343–348  
   transport of RNAs, 348–349  
   viruses and, 342  
 Nucleolar organizing regions, 358

- Nucleolus  
 animal and plant cells, 7*f*  
 biomolecular condensates and, 297, 357, 358–360  
 dynamic structure of, 359–360  
 nuclear membrane and, 337*f*  
 nucleolar organizing regions, 358–359  
 nucleolus-associated domains, 354  
 number per nucleus, 357*t*  
 rRNA transcription, processing and ribosome assembly, 357–360
- Nucleolus-associated domains (NADs), 354
- Nucleoplasmin, 343, 345
- Nucleoporins (NUPs), 340, 343
- Nucleoside triphosphates, 46
- Nucleosides, 54, 55
- Nucleosome core particles, 154
- Nucleosome remodeling factors, 155
- Nucleosomes  
 absence at promoters and enhancers, 253  
 chromatin organization in, 153–154  
 chromatin remodeling factors and, 254  
 disassembly and reassembly during DNA replication, 170  
 epigenetic inheritance and, 158  
 histone modifications, 249–253  
 structure, 249
- Nucleotide-excision repair, 182–184
- Nucleotides  
 components of, 54  
 functions of, 57  
 genetic code, 93–95  
 polymerization, 55
- Nucleus  
 animal and plant cells, 7*f*  
 breakdown during apoptosis, 647, 648*f*  
 description of, 6  
 extrusion from erythrocytes, 338  
 fragmentation during apoptosis, 651  
 nuclear bodies, 356–362  
 nuclear envelope, 336–340 (*see also* Nuclear envelope)  
 nuclear pore complexes, 340–343  
 organization of chromatin, 350–356  
 overview, 336  
 positioning by intermediate filaments, 495  
 secretory pathway and, 368  
 selective transport of proteins, 343–348, 349–350  
 transport of RNAs, 348–349  
 viruses and, 342
- Numerical aperture, 26
- NUPs. *See* Nucleoporins
- Nurse, Paul, 606
- O**
- Oct4, 643
- Oculodentodigital dysplasia, 558*t*
- Odor detection, 571–572, 576
- Odorant receptors, 571–572, 576
- Ohsumi, Yoshinori, 407
- Okazaki, Reiji, 164
- Okazaki fragments, 164–166, 167, 169*f*, 170
- Oleate, 51*f*
- Oligonucleotides, 55
- Oligosaccharides  
 defined, 50  
 functions of, 51  
 glycocalyx, 510  
 GPI-anchored proteins, 381*f*  
 protein glycosylation and, 380, 390–392  
 transmembrane proteins and, 507
- Oligosaccharidetransferase, 380
- O-linked glycoproteins, 286, 287
- O-linked glycosylation, 391–392
- O-linked oligosaccharides, 391–392
- Oncogenes  
*bcl-2* oncogene, 650, 651  
 cancer genomics and, 685–686  
 defined, 667  
 functions of oncogene products, 674–679  
 in human cancer, 671–673, 674*f*  
 identification in Rous sarcoma virus, 22  
 inherited cancer susceptibility and, 688  
 proto-oncogenes, 669–671  
*ras* oncogenes, 583 (*see also* *ras* oncogenes)  
 retroviral oncogenes, 668–669
- Oncogene-targeted drugs, 688–692
- Oocytes  
 cell cycle regulation at G<sub>2</sub> phase, 602  
 maturation promoting factor, 604, 605–606
- Opa1. *See* Optic atrophy 1
- Opdivo (nivolumab), 694
- Open reading frames, 96*f*, 97, 305
- Operator, *lac* operon and, 231, 232
- Operons, 231  
*See also lac* Operon
- Opossum, 309*f*
- Optic atrophy 1 (Opa1), 414, 415*f*
- ORC. *See* Origin recognition complex
- ORC proteins, 613, 614*f*, 615
- Organelles  
 eukaryotic cells, 6, 7*f*, 8  
 protein composition analysis, 318–319  
 subcellular fractionation, 34–36  
 transport and positioning by microtubules and motor proteins, 486–487
- Organic molecules  
 carbohydrates, 49–51  
 introduction and overview, 48–49  
 lipids, 51–53  
 nucleic acids, 53–57, 58*f*  
 origin of life, 2, 3*f*  
 proteins, 58–67
- Origin of replication (Ori)  
 bacteria and viruses, 171–172  
 defined, 171  
 eukaryotic cells, 172–173  
 plasmid vectors and, 102–103  
 properties of eukaryotic origins, 173–176
- Origin recognition complex (ORC), 174–175
- Origin recognition complex proteins (ORC proteins), 613, 614*f*, 615
- OS9, 382*f*, 383
- Osmotic balance, 527
- Outer chloroplast membrane, 439–440, 446, 447
- Outer mitochondrial membrane  
 import of nuclear-encoded mitochondrial proteins, 435–436  
 in mitochondrial fission and fusion, 414, 415*f*  
 structure and composition, 412, 413*f*, 414  
 Tom complex, 433
- Outer nuclear membrane, 336–337, 342
- Ovarian carcinomas, 673
- Ovaries, steroid-producing cells in, 386
- Oxa1 translocase, 434*f*, 435
- Oxaloacetate, 420
- Oxidation–reduction reactions, NADH as an electron carrier, 72
- Oxidative catabolism  
 of fatty acids, 421  
 of glucose, 417–421  
 overview of pathways for ATP synthesis, 411–412
- Oxidative decarboxylation, of pyruvate, 419
- Oxidative metabolism  
 catabolism of fatty acids, 421  
 catabolism of glucose, 417–421  
 defined, 5  
 evolution of metabolism, 5  
 oxidative phosphorylation, 422–428  
 summary of, 429*f*
- Oxidative phosphorylation  
 ATP synthesis and, 412, 417, 419, 421  
 location of enzymes in the mitochondria, 413*f*, 414  
 mechanisms of the electron transport chain, 425–427  
 overview and description of chemiosmotic coupling, 422–425  
 proton flow and ATP production by ATP synthase, 427–428
- Oxidative reactions, in peroxisomes, 452
- Oxygen  
 hydrogen bonds, 43  
 oxidative metabolism, 5  
 in oxidative phosphorylation, 422, 425*f*, 426
- Oxytocin, 469
- P**
- P (peptidyl) site, 271, 272
- p15 Cdk inhibitor, 683
- p16 Cdk inhibitor, 684
- p21 Cdk inhibitor, 616, 653, 683
- p27 Cdk inhibitor, 612, 613*f*, 683
- p38 MAP kinase, 585, 586*f*
- p53 protein  
 apoptosis and, 653, 654*f*, 655, 684–685  
 cancer genomics and, 686  
 mutations and human cancer, 616  
 a nuclear localization and nuclear export signal, 345*t*
- p53* tumor suppressor gene, 682, 683, 685
- p57 Cdk inhibitor, 683
- p120 protein, 465*f*
- PABP. *See* Poly-A binding protein

- Palade, George, 32, 366–367
- Palbociclib (Ibrance), 689*t*
- Palmitate, 51*f*
- Palmitic acid, 79, 287*f*, 509
- Palmitoylation, 287
- Pancreas
  - acinar cells, 366–367
  - cystic fibrosis and, 529
- Pancreatic cancer, 661*f*
- Pantothenate, 73*t*
- Papillomaviruses, 22, 23*f*, 682
- Paracrine signaling, 564, 567–568
- Paramecium, 10, 11*t*, 488
- Paramecium tetraurelia, 11*t*
- Parenchyma, 12
- Parkin* gene, 408
- Parkinson's disease, 281–282, 408, 640
- Passive diffusion, 341
- Passive transport, 80
- Pathogenic bacteria
  - disruption of junctional complexes by, 557
  - subversion of normal actin cytoskeleton and, 467
- Pauling, Linus, 64, 89
- Paxlovid™, 286
- P-cadherin, 556
- PCNA protein, 167, 169*f*, 355*f*, 612
- PD-1, 694
- PDGF. *See* Platelet-derived growth factor
- PDGFR. *See* Platelet-derived growth factor receptor
- PDI. *See* Protein disulfide isomerase
- PK1 protein kinase, 587, 588*f*
- Pea plants, 85–86
- Pectins, 393, 544, 545
- Pembrolizumab, 694
- Pen-2 protein, 592, 593*f*
- Penicillin, 542
- Peppered moth, 149
- Peptide bonds
  - catalytic activity of rRNAs and, 267
  - definition and formation of, 60, 61*f*
  - hydrolysis by serine proteases, 70–71
  - protein folding and, 285
- Peptide hormones, 568, 569
- Peptidoglycan, 542, 543*f*
- Peptidyl prolyl isomerase, 285
- Peptidyl transferase reaction, 267
- Peptidyl tRNA, 272
- Pericentriolar material, 480, 481
- Perinuclear space, 337
- Peripheral membrane proteins
  - definition and characteristics of, 79, 507
  - fluid mosaic model of membrane structure, 77*f*, 506*f*
  - red blood cells, 508
- Peripherin, 493*t*
- PERK stress sensor, 383, 384
- Peroxis (Pex proteins), 453, 454–455
  - Pex5, 454–455
  - Pex7, 454
  - Pex13, 454*f*, 455
  - Pex14, 454*f*, 455
  - Pex17, 454*f*, 455
- Peroxisomal ER, 453–454
- Peroxisome biogenesis disorders, 453
- Peroxisome targeting signal 1 (PTS1), 454
- Peroxisome targeting signal 2 (PTS2), 454
- Peroxisomes
  - animal and plant cells, 7*f*
  - assembly, 453–455
  - fission of, 455
  - overview and functions of, 8, 411, 451, 452
  - secretory pathway and, 367–368
- Personal genomics, 314
- Pex proteins. *See* Peroxis
- Pfizer pharmaceutical company, 330, 331–332
- pH, internal pH of lysosomes, 403
- PH domain. *See* Pleckstrin homology domain
- Phagocytosis
  - apoptosis and phagocytic cells, 648, 649*f*
  - cell surface protrusions involved in, 466, 467*f*
  - definition and description of, 532
- Phagolysosomes, 532
- Phagophores, 406*f*, 407
- Phagosomes, 532
- Phase-contrast microscopy, 26–27
- Phenotype, 85
- Phenylalanine
  - cystic fibrosis and, 281
  - genetic code, 94*f*, 95
  - structure and properties of, 59
- 2-Phenylaminopyrimidine, 691
- Phenylketonuria, 92
- Pheophytin, 443
- Philadelphia chromosome, 674*f*, 689, 690
- Phloem, 12
- Pho4 transcription factor, 349–350
- Phosphates
  - high-energy bonds, 46
  - hydrolysis of ATP and, 46, 47
  - nucleotides, 54
  - phospholipids, 52
  - protein phosphorylation, 290–294
  - substrate-level phosphorylation, 423
  - transport across the inner mitochondrial membrane, 436–437
- Phosphatidic acid, 52*f*, 385
- Phosphatidylcholine
  - in cell membranes, 503, 505*f*
  - in plasma membranes, 76
  - structure, 52*f*, 504*f*
  - synthesis in the smooth ER, 385–386
  - synthesis of sphingomyelin and glycolipids, 392*f*, 393
  - transport to the mitochondria, 436
- Phosphatidylethanolamine
  - autophagosomes and, 407
  - in cell membranes, 503, 505*f*
  - in plasma membranes, 76
  - structure, 52*f*, 504*f*
  - synthesis in mitochondria, 436
  - synthesis in the smooth ER, 385–386
- Phosphatidylinositol (PI) 3-kinase
  - cancer genomics and, 686
  - defined, 586
  - oncogene protein, 678, 692
  - PI 3-kinase/Akt pathway, 586–588 (*see also* PI 3-kinase/Akt pathway)
  - PTEN protein and, 683
- Phosphatidylinositol
  - in cell membranes, 503, 505*f*
  - in plasma membranes, 76
  - structure, 52*f*, 504*f*
  - synthesis in the smooth ER, 385–386
  - transport to the mitochondria, 436
- Phosphatidylinositol 3,4,5-bisphosphate (PIP<sub>3</sub>), 586–587, 588*f*, 654, 683
- Phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>), 586, 587*f*, 588*f*, 654
- Phosphatidylserine
  - apoptosis and, 648, 649*f*, 651
  - in cell membranes, 503, 505*f*
  - lipid-anchored membrane proteins and, 510
  - mitochondrial synthesis of
    - phosphatidylethanolamine from, 436
  - in plasma membranes, 76
  - programmed cell death and, 503
  - structure, 52*f*, 504*f*
  - synthesis in the smooth ER, 385–386
  - transport to the mitochondria, 436
- Phosphodiester bonds, 55
- Phosphoenolpyruvate, 418*f*, 419
- Phosphofructokinase, 417, 418*f*
- Phosphoglucose isomerase, 418*f*
- 3-Phosphoglycerate, 418*f*, 419, 445*f*
- Phospholipid bilayers
  - characteristics of membrane lipids, 76–77
  - defined, 76
  - fluid mosaic model of membrane structure, 77, 78, 79
  - selective permeability and diffusion across, 79–80
- Phospholipid transfer proteins, 436
- Phospholipids
  - cardiolipin of mitochondria, 413*f*, 414
  - characteristics of membrane lipids, 76–77
  - membrane fluidity and, 505
  - origin of cells, 4
  - plasmalogens, 452
  - properties of, 4
  - structure and function, 52–53, 504*f*
  - structure of low-density lipoproteins and, 535*f*
  - synthesis in the smooth ER, 385–386
  - types in cell membranes, 503, 504*f*, 505
- Phosphorylase kinase, 292, 293*f*, 299–300, 574, 575*f*
- Phosphorylation
  - of enzymes, 74–75
  - glycogen breakdown cascade, 300
  - histone modification and, 252, 253
  - of intermediate filament proteins, 495
  - protein kinase A and, 575–576, 577*f*
  - of proteins, 290–294, 575–576, 577*f*
  - regulation of global translation and, 276*f*, 277
  - regulation of transcription factor import into the nucleus and, 349–350
  - substrate-level phosphorylation of ATP, 423
  - See also* Autophosphorylation; Oxidative phosphorylation

- Phosphorylcholine group, 392*f*, 393  
 Phospho-specific antibodies, 292  
 Phosphotyrosine, 294, 295*f*  
 Photolyses, 181  
 Photons, light reactions of photosynthesis, 442  
 Photoreactivation, 181  
 Photosynthesis  
   chloroplast genome and, 446  
   dark reactions, 445–446  
   definition and overview of, 438  
   evolution of metabolism, 5  
   light reactions, 442–444  
   overall equation for, 442  
 Photosystems  
   functions of, 441  
   photosystem I, 443, 444, 446  
   photosystem II, 443, 444, 446  
 PI 3-kinase. *See* Phosphatidylinositol 3-kinase  
 PI 3-kinase oncogene protein, 678, 692  
 PI 3-kinase/Akt pathway  
   cell cycle regulation and, 600, 612  
   crosstalk and, 595  
   oncogenic activity and cell survival, 678–679  
   overview and description of, 586–588  
   promotion of cell survival, 654–655  
 Pick's disease, 283  
 Piebaldism, 19*f*  
*PINK1* gene, 408  
 Pituitary gland, 568  
 PKA. *See* Protein kinase A  
 Placental cadherin, 556  
 Plakins, 495, 496*f*  
 Plakoglobin, 496*f*, 556*f*  
 Plakophilin, 496*f*, 556*f*  
 Plant cell walls  
   cell expansion and, 545–546  
   components and functions of, 544–545  
   cytokinesis and, 626  
   plasmodesmata, 559, 560*f*  
   polysaccharide synthesis in the Golgi apparatus, 393  
   structure of cellulose, 543–544  
 Plant hormones, 568  
 Plants/Plant cells  
   aquaporins, 514  
   characteristics of introns and exons in, 140*t*  
   cytokinesis, 626  
   evolution of cells, 9*f*  
   gene transfer, 122  
   genome size, 11*t*, 135, 136*f*  
   mitochondrial genome, 430  
   organization of microtubules in, 480  
   peroxisomes, 452  
   plasmodesmata, 559, 560*f*  
   synthetic biology and, 330  
   tissue systems and cell types, 12, 13*f*  
 Plasma membrane  
   animal and plant cells, 7*f*  
   association of actin filaments with, 462–465  
   blebbing during apoptosis, 651  
   caveolae, 512  
   cell surface protrusions and cell movement, 466–468  
   cytokinesis in animal cells, 625  
   cytokinesis in plant cells, 626  
   endocytosis, 531–538  
   gap junctions, 557, 559  
   lipid bilayer, 502–505  
   lipid composition, 76  
   membrane domains, 510–512  
   microvilli, 465–466  
   in necroptosis and pyroptosis, 656  
   plasma membrane proteins, 506–510  
     (*see also* Plasma membrane proteins)  
   plasmodesmata, 559, 560*f*  
   secretory pathway and, 367, 368*f*  
   structure, 502–512  
   subcellular fractionation, 34, 35*f*  
   transport by coated vesicles and, 400  
   transport of small molecules across, 513–530  
     (*see also* Small molecule transport)  
   tunneling nanotubes, 560  
 Plasma membrane domains, 510–512  
 Plasma membrane proteins  
   classes of, 507  
   export from the Golgi apparatus, 393, 394–395  
   fluid mosaic model of membrane structure, 506–507  
   glycocalyx, 510  
   lipid-anchored proteins, 508–510  
   overview, 506  
   plasma membrane domains and, 510–512  
   of red blood cells, 508  
   secretory pathway, 374  
 Plasmacytomas, 672–673  
 Plasmalogens, 452  
 Plasmids  
   in cDNA cloning, 105*f*, 106  
   CRISPR/Cas system and, 128, 129–130  
   expression plasmids in gene transfer, 119, 120*f*, 121  
   expression vectors, 108  
   in molecular cloning, 101–105  
   reporter plasmids, 236  
   *in vitro* mutagenesis, 122, 123*f*  
 Plasmodesmata, 7*f*, 559, 560*f*, 626  
 Plasmodium, 330  
 Plasmodium falciparum, 330  
 Plastids  
   chloroplasts, 438–449  
   definition and types of, 449  
   development and interconversion of, 449–450  
 Plastocyanin, 443, 444*f*  
 Plastoquinone, 443, 444*f*  
 Platelet-derived growth factor (PDGF), 569, 578, 631  
 Platelet-derived growth factor receptor (PDGFR), 674–675, 689*t*, 690, 691  
 Platelets, 554–555, 631, 634  
 Platypus, 309*f*  
 Pleckstrin homology (PH) domain, 587  
 Plectin, 497, 553*f*  
 Pluripotency  
   defined, 639  
   of embryonic stem cells, 639–642  
   induced pluripotent stem cells, 642, 643–645  
 PML body, 357*t*  
*PML/RAR $\alpha$  oncogene protein*, 677  
*Pneumococcus*, 88  
 Point mutations, 672  
 Polar amino acids, 59*f*, 60  
 Polar covalent bonds, 41  
 Polar molecules, 41, 43, 44  
 Poliovirus, 97  
 Polo-like kinases, 620, 621, 622, 625  
 Poly-A binding protein (PABP), 270  
 Poly-A exonuclease, 275  
 Poly-A polymerase, 217  
 Poly-A tail, 215*f*, 216–217, 226, 275  
 Polyacrylamide, 101  
 Polyadenylation, 215*f*, 216–217  
 Polyadenylation signals, 208, 209*f*  
 Polycistronic mRNAs, 268  
 Polyclonal antibodies, 115  
 Polycomb bodies, 357*t*, 360, 361*f*  
 Polycomb proteins, 255–256  
 Polycomb Repressive Complex 1 and 2 (PRC1 and 2), 255–256, 259, 360, 361*f*  
 Polymerase chain reaction (PCR)  
   overview and description of, 110–112  
   *in vitro* mutagenesis, 122, 123*f*  
 Polynucleotides, 55–57  
 Polyomaviruses, 294, 666*t*  
 Polypeptides  
   basic model of gene expression, 96–97  
   folding, 281–285 (*see also* Protein folding)  
   peptide bonds and the formation of, 60, 61*f*  
   protein structure, 61–67  
   proteolysis, 285–286  
   regulation of proteins by, 295  
 Polyproteins, 286  
 Polyps, 186, 662  
 Polysaccharides  
   defined, 50  
   of the extracellular matrix, 548–550  
   structure and function, 49–51  
   synthesis in the Golgi apparatus, 393  
   *See also* Cell wall polysaccharides  
 Polysomes (polyribosomes), 270  
 Polytene chromosomes, 351  
 Polyubiquitin, 298  
 Porins, 413*f*, 414, 514  
 Porphyrin ring, 441, 442  
 Porter, Keith, 32  
 Position weight matrix, 241  
 Positive staining, 33  
 Positive transcription-elongation factor-b (P-TEFb), 246, 247*f*, 248  
 Post-synaptic neurons, 516, 517*f*, 519, 520  
 Potassium ions  
   action potentials and, 520, 522, 523*f*  
   active transport by the Na<sup>+</sup>-K<sup>+</sup> pump and, 525–527

- intracellular and extracellular concentrations  
in mammalian cells, 517*t*  
resting membrane potential and, 517–518
- PRC1 and 2. *See* Polycomb Repressive Complex 1 and 2
- Premature aging syndromes, 177, 340
- Pre-mRNAs  
alternative splicing, 222–223, 225  
defined, 137  
mRNA export from the nucleus and, 348  
processing and splicing, 215–222
- Prenyl groups, 506*f*; 509
- Prenylation, 287
- Preproinsulin, 285
- Pre-rRNAs  
defined, 212  
processing of, 212–213  
removal of introns by splicing, 215  
self-splicing, 219, 221  
tRNAs and, 214
- Presequences, 433–434
- Pre-synaptic neurons, 516, 517*f*; 519, 520
- Pre-tRNAs, 214, 215
- Primary cilia, 488, 489*f*
- Primary cultures, 20
- Primary RNA transcript, 137
- Primary structure of proteins, 64
- Primase, 164–165, 169*f*; 170
- Primers  
in next-generation sequencing, 311  
in the polymerase chain reaction, 111–112  
in Sanger sequencing, 106, 107*f*  
*in vitro* mutagenesis, 122, 123*f*
- Prion protein (PrP), 281*t*, 282–283
- Prions, 281*t*, 282–283
- Proapoptotic effector proteins, 652–653
- Proapoptotic regulatory proteins, 652, 654, 655*f*; 656
- Procaspases, 651
- Processed pseudogenes, 151
- Procollagens, 547
- Products  
in chemical reactions, 41–42  
of enzymatic catalysis, 68–69
- Profilin, 460–461, 468
- Progesterone, 565
- Programmed cell death  
alternative pathways, 656  
apoptosis, 647–656 (*see also* Apoptosis)  
cancer cells and, 665  
definition and overview of, 647  
oncogenes and the blocking of, 677–679  
phosphatidylserine and, 503
- Programmed cell death 1 (PD-1), 694
- Programmed DNA rearrangements, 191–196
- Proinsulin, 285
- Prokaryotes  
characteristics of, 5–6  
chromosomes in, 153  
features of introns and exons in, 139, 140*t*  
genome size, 10, 11*t*, 135, 136*f*  
mRNA structure and the initiation of translation, 268, 269*f*  
prokaryotes and eukaryotes compared, 6*t*
- Proliferating cell nuclear antigen (PCNA), 167
- Proline  
in collagen, 547  
genetic code, 94*f*; 95  
protein folding and, 285  
structure and properties of, 59–60
- Prolyl hydroxylase, 547
- Prometaphase, 618–619, 623
- Promoters  
bacterial, 200–202  
chromatin characteristics and, 253  
DNA looping and, 238  
eukaryotic promoters, 236–237  
in eukaryotic transcription, 205, 206*f*  
histone modifications and, 253  
of ribosomal RNA genes, 208, 210*f*  
topologically associated domains and interaction with enhancers, 239–240  
transcription factor binding sites, 240–243
- Proofreading, 171
- Prophase, 156*f*; 617–618, 619*f*
- Proplastids, 449–450
- Prosthetic groups, 71
- Protease inhibitors, 286
- Proteases  
cancer cells and, 552, 664  
caspases, 649, 651  
digestion of the extracellular matrix, 552, 553  
protein analysis and, 317  
treatment of AIDS and, 70
- Proteasomes, 297–299
- Protein 4.1, 463–464, 508
- Protein complexes, analysis of, 319
- Protein Data Bank, 64
- Protein disulfide isomerase (PDI), 283–284, 380, 387
- Protein domains  
definition and overview of, 64–65  
SH2 domains, 579, 580, 581  
*See also* Transmembrane domains
- Protein folding  
chaperones and, 278–281  
enzymes that catalyze, 283–285  
misfolding diseases, 281–284  
quality control in the rough ER, 381–385  
in the rough ER, 379–380
- Protein kinase A (PKA)  
cAMP pathway and, 574–576  
glycogen breakdown cascade, 299–300  
protein phosphorylation and, 575–576, 577*f*  
recognition motifs and phosphorylation sites, 291–292  
regulation of, 295–296
- Protein kinases  
definition and overview of, 290–291  
discovery of tyrosine kinases, 294–295  
kinomics, 292  
mechanisms of specificity, 291–292  
protein phosphorylation and, 290–294  
regulation of global translation and, 276*f*; 277  
regulation of import into the nucleus, 349  
types of, 291
- Protein misfolding diseases, 281–284
- Protein phosphatases, 292, 575–576, 577*f*
- Protein processing and sorting  
glycosylation within the Golgi apparatus, 390–392  
insertion of transmembrane proteins into the rough ER membrane, 373–379  
mechanism of vesicular transport, 396–401  
overview, 365  
protein folding and processing in the rough ER, 379–381  
protein movement through the Golgi apparatus, 389–390  
protein sorting and export from the Golgi apparatus, 393–396  
secretory pathway, 366–368  
targeting proteins to the rough ER, 368–373
- Protein regulation  
cascades of regulation, 299–300  
degradation, 297–299  
dephosphorylation, 292  
other modifications, 294–295  
overview, 288–289  
phosphorylation, 290–294  
protein–protein interactions, 295–297  
by small molecules, 289–290
- Protein regulation cascades  
analysis of, 326–327  
overview and description of, 299–300  
*See also* Signal transduction pathways
- Protein splicing factors, 218, 222
- Protein synthesis  
attachment of carbohydrates and lipids, 286–287  
basic model of protein-encoding gene expression, 95–97  
central dogma of molecular biology, 93  
experiments elucidating, 92  
genetic code, 93–95  
overview, 263  
protein cleavage, 285–286  
protein export from the endoplasmic reticulum, 386–388  
protein folding, 281–285 (*see also* Protein folding)  
role of messenger RNA, 93  
transcription of DNA into RNA (*see* Transcription)  
translation of mRNA, 263–277 (*see also* Translation)
- Protein-coding genes  
chimpanzee genome, 310  
chloroplast genome, 446  
genomes of non-human vertebrates, 308–310  
human genome, 305, 307–308, 310  
Neanderthal genome, 310  
organismal complexity and, 305, 307–308  
transcriptomics, 314–315, 316
- Protein-coding sequences  
alternative splicing and, 142  
human genome, 145*t*, 305  
introns, exons, and RNA splicing, 137–141

- versus long noncoding RNAs in  
representative genomes, 146*t*  
nested genes, 141  
relative size of eukaryotic genomes and,  
135–136  
*See also* Exons
- Protein–protein interactions  
analysis of, 319–322  
biomolecular condensates and, 357  
examination by co-immunoprecipitation,  
117  
glycogen breakdown cascade, 300  
liquid–liquid phase separation, 296–297  
regulation of Cdks, 610  
regulation of enzyme activity, 74–75  
regulation of protein activity, 295–297
- Proteins  
antibodies as probes for, 114–117  
autophagy and, 407  
composition and polypeptide synthesis,  
58–60, 61*f*  
definition and overview, 58  
degradation, 297–299  
denaturation and refolding, 62, 63–64  
enzymes, 68–75 (*see also* Enzymes)  
GFP-fusion proteins, 124–125  
import and sorting of chloroplast proteins,  
446–449  
import of nuclear-encoded mitochondrial  
proteins, 432–436  
intermediate filament proteins, 493–494  
large-scale analysis of (*see* Proteomics)  
matrix structural proteins, 546–548  
membrane proteins, 77, 78, 79  
phosphorylation of, 290–294, 575–576,  
577*f*  
processing and sorting (*see* Protein  
processing and sorting)  
proteoglycans, 549–550  
recombinant proteins, 108–109  
regulation (*see* Protein regulation)  
selective transport into and out of the  
nucleus, 341, 343–348, 349–350  
structure and folding, 61–67 (*see also*  
Protein folding)  
synthesis (*see* Protein synthesis)  
*See also* specific proteins and protein groups
- $\alpha$ -Proteobacteria, 430
- Proteoglycans, 392, 549–550, 551
- Proteolysis  
protein cleavage, 285–286  
protein degradation, 297–299
- Proteome, 317
- Proteomics  
definition and overview of, 316–317  
global analysis of protein localization,  
318–319  
identification of cell proteins, 317–318  
protein interactions, 319–322
- Protists, 9*f*
- Proton gradients  
ATP production by ATP synthase and,  
427–428
- ATP production in chloroplasts, 440, 441  
ATP production in photosynthesis and,  
442, 443, 444  
brown fat and heat production, 427  
chemiosmotic theory and, 423–425  
oxidative metabolism in mitochondria and,  
429*f*  
in oxidative phosphorylation, 422–423  
production by the electron transport chain,  
425–427
- Proton pumps, 403, 527
- Protons  
active transport of, 527, 530  
*See also* Proton gradients
- Proto-oncogenes, 669–671, 672, 673
- PrP. *See* Prion protein
- Prusiner, Stanley, 282
- P-selectin, 555
- Pseudogenes, 141, 145*t*, 150, 151–152
- Pseudopodia, 466, 467, 532
- P-TEFb. *See* Positive transcription-elongation  
factor-b
- PTEN tumor suppressor gene, 683, 686
- PTS1 and PTS2, 454
- Pulse-chase experiments, 366–367
- PUMA protein, 653, 684
- Purines, 54, 89–90  
*See also* Adenine; Complementary base  
pairing; Guanine
- Pyridoxal (vitamin B<sub>6</sub>), 73*t*
- Pyridoxal phosphate, 73*t*
- Pyrimidines  
defined, 54  
DNA structure, 89–90  
UV light and pyrimidine dimers, 180*f*, 181  
*See also* Complementary base pairing;  
Cytosine; Thymine; Uracil
- Pyrophosphate, 46*f*, 47, 50
- Pyroptosis, 656
- Pyrrrolysine, 267
- Pyruvate  
glycolysis, 417, 418*f*, 419  
overview of catabolic pathways for ATP  
synthesis, 411, 412*f*  
oxidative decarboxylation, 419  
oxidative metabolism in mitochondria and,  
429*f*  
transport into the mitochondrial matrix,  
437
- Pyruvate decarboxylase, 418*f*
- Pyruvate dehydrogenase, 419*f*
- Q**
- Quaternary structure of proteins, 66
- R**
- Rab proteins, 401
- Rab1, Carl, 351
- Rac protein, 586*f*
- RAD genes, 182
- RAD51 protein, 188, 189*f*, 190
- Radiation, cancer and, 666
- raf* oncogene, 669, 671, 675, 686
- Raf proteins  
ERK MAP kinase pathway, 584*f*, 585, 586  
*raf* oncogene and, 671, 675  
Ras/Raf/MEK/ERK pathway, 595, 611,  
612, 655  
signaling feedback loops and, 327
- RAG1 and RAG2 proteins, 193–194
- “Railroad track” morphology, 503
- Ramón y Cajal, Santiago, 360
- RAN protein, 345, 346, 347–348
- Rapoport, Tom, 372
- ras* oncogenes  
cancer and oncogenic Ras proteins, 672,  
675  
oncogene-targeted drugs and, 692  
Ras signaling and cancer, 583, 686  
as retroviral oncogenes, 669  
tumor suppressor genes and, 685  
*ras*H, 672, 692  
*ras*K, 685, 686, 692  
RasKG12C protein, 689*t*  
RasN protein, 692
- Ras proteins  
active and inactive forms, 290  
ERK MAP kinase pathway, 582, 584–585,  
586  
lipid modifications, 287  
lipid-anchoring in the plasma membrane,  
509*f*, 510  
oncogenic (*see ras* oncogenes)  
Ras/Raf/MEK/ERK pathway, 595, 611,  
612, 655
- Ras/Raf/MEK/ERK pathway  
Bad protein and cell survival, 655  
crosstalk and, 595  
cyclin D synthesis and, 611  
progression through the G<sub>1</sub> restriction point  
and, 612
- Rats  
conservation of functional gene regulatory  
elements, 326*f*  
human genome research and, 308  
vertebrate genome evolution and, 309*f*
- Rb protein family, 611–612
- Rb* tumor suppressor gene, 680–682, 684
- Reactants, in chemical reactions, 41–42
- Reaction centers, 442*f*, 443
- Real-time PCR, 112
- Receptor tyrosine kinases  
ERK MAP kinase pathway and, 584–585  
as oncogene proteins, 675  
overview and description of, 578–579, 580*f*  
PI 3-kinase and, 586  
proliferation of skin fibroblasts and, 631
- Receptor-mediated endocytosis, 533  
*See also* Clathrin-mediated endocytosis
- Recessive genes, 85–86
- Recognition motifs, of protein kinases,  
291–292
- Recombinant DNA technology  
DNA sequencing, 106–107  
molecular cloning, 101–106  
overview, 100

- recombinant proteins, 108–109
- restriction endonucleases, 100–101, 102*f*
- Recombinant molecules, 103–105
- Recombinant proteins, 108–109
- Recombination
  - homology-directed repair and, 188–190
  - between repetitive sequences, 149*f*
- Recombination signal (RS) sequences, 193–194
- Recycling endosomes, 393, 394*f*; 395, 404, 405*f*
- Red blood cells. *See* Erythrocytes
- Reese, Thomas, 484–485
- Refractive index, 26
- Regenerative medicine
  - applications of adult stem cells, 637–638
  - embryonic stem cells and, 639, 640, 642
  - induced pluripotent stem cells and, 644, 645
  - somatic cell nuclear transfer and, 642, 643
  - therapeutic cloning, 643
  - in vivo* transdifferentiation and, 646
- Regulated secretory pathway, 393–394
- Regulatory protein kinases, regulation of global translation and, 276*f*, 277
- RelA protein, 345*t*
- Release factors, 272
- Remdesivir, 286
- Renal cell carcinoma, 689*t*
- Repetitive sequences, 147–149, 157
- Replication factor C (RFC), 167, 170
- Replication factories, 355, 356
- Replication fork
  - accessory proteins, 167–169
  - discovery of, 164
  - DNA synthesis in leading and lagging strands, 164–167
  - replisomes, 169–170
  - translesion DNA synthesis, 185–187
- Replication protein A (RPA), 168, 183, 184*f*
- Replisomes, 169–170
- Reporter plasmids, 236
- Repression domains, 245, 246*f*
- Repressors
  - catabolite repressor protein, 234
  - histone modifications and, 251, 253
  - lac* repressor, 231–233, 234, 289
  - of transcriptional activators, 245, 246*f*
  - translational repression proteins, 273–274
- Reproductive cloning, 643
- Resolution
  - defined, 25
  - electron microscopy, 32–33
  - light microscopy, 25–26
- Resonance energy transfer, 442–443
- Resting membrane potential, 517–518, 522, 523*f*
- Restriction endonucleases, 100–101, 102*f*, 112, 113*f*
- Restriction point
  - definition and overview of, 601–602
  - growth factors and control of progression through, 610–612, 613*f*
  - oncogene cell cycle regulators and, 676
  - tumor suppressor genes and, 684
- Reticulocytes, 634*f*
- Retinoblastoma, 611, 680–682
- Retinoic acid, 565, 677
- Retinoic acid receptor, 677
- Retinoids, 565
- Retrogenes, 150–152
- Retrotranslocons, 382*f*; 383
- Retrotransposition, 150–152
- Retrotransposons, 147–149
- Retroviral oncogenes, 668–669
- Retroviruses
  - adult T-cell leukemia and, 666*t*
  - definition and description of, 97–98
  - entry into the nucleus, 342
  - retroviral oncogenes, 668–669
  - reverse transcription and, 98
  - as vectors in gene transfer, 121
- Retrovirus-like elements, 147*t*, 148
- Reverse transcriptases
  - cDNA cloning, 105–106
  - definition and description of, 98
  - DNA provirus and, 98–99
  - generation as a recombinant protein, 108
  - retrotransposons and, 147–148
  - retroviruses and, 98
  - telomerase, 159, 176, 177, 178*f*; 361
- Reverse transcription
  - cDNA cloning, 105–106
  - defined, 98
  - DNA provirus and, 98–99
  - gene duplication and retrogenes, 150–152
  - RNA viruses and, 97–98
- RFC protein, 167, 170, 612
- RGS proteins, 573
- Rheb protein, 588, 589*f*
- Rhesus monkeys, 309*f*
- Rho protein family
  - cell migration and, 467–468
  - MAP kinase pathways and, 585, 586*f*
- Ribbon models, 65*f*
- Riboflavin (vitamin B<sub>2</sub>), 73*t*
- Ribonuclease (RNase), 62, 63–65
- Ribonucleic acid (RNA)
  - analysis of protein–RNA interactions, 321–322
  - antisense RNA, 130, 131*f*
  - basic model of gene expression, 96–97
  - cDNA cloning, 105–106
  - central dogma of molecular biology, 93
  - chloroplast genome and, 446
  - components and structure of, 54–55, 56, 57*f*
  - CRISPR/Cas system and, 128, 129, 130*f*
  - databases, 146
  - degradation, 226–227
  - differences with DNA, 93
  - direction of polymerization, 55
  - functions of, 53–54
  - multivalent interactions and, 297
  - nucleic acid hybridization, 112, 113
  - nucleocytoplasmic transport, 340–341, 348–349
  - retroviruses and, 148
  - RNA editing, 225–226
  - RNA viruses, 23*f*
  - self-replication and the origin of life, 3, 4
  - self-splicing, 219, 221–222
  - in spliceosomes, 218–219, 222
  - structure and information storage, 56, 57, 58*f*
  - synthetic biology and, 329, 330, 331–332
  - telomerase and, 176, 177, 178*f*; 361
  - transcription and, 3–4
  - transcriptomics, 314–316
  - translation and, 4
- Ribonucleoprotein, 220
- Ribonucleotide triphosphates (NTPs), 200, 202
- Ribose, 46, 54, 213
- Ribosomal RNA (rRNA)
  - catalytic activity of, 266–267
  - defined, 93
  - degradation, 226
  - export from the nucleus, 348
  - functions of, 53–54
  - processing of, 212
  - in ribosomes, 266
  - role in mRNA translation, 272
  - species of in eukaryotes and bacteria, 204, 212
  - transcription, processing and ribosome assembly in the nucleolus, 357–360
- Ribosomal RNA genes
  - chloroplast genome, 446
  - gene amplification in amphibian oocytes, 196
  - human genome, 357
  - localization in the nucleolus, 358
  - mitochondrial genome, 430–431
  - RNA polymerases and the transcription of, 204, 208, 210, 211*f*; 357, 359
- Ribosomes
  - animal and plant cells, 7*f*
  - assembly in the nucleolus, 357–360
  - basic model of gene expression, 96
  - catalytic activity of rRNAs, 266–267
  - chloroplast genome and, 446
  - cotranslational pathway and, 370, 371*f*; 372–373
  - description and structure of, 264, 266
  - initiation of translation and, 268–271
  - inner nuclear membrane and, 337
  - RNA components of, 357
  - secretory pathway and, 368
  - sites for tRNA binding, 271–272
  - subcellular fractionation, 34, 35*f*; 36
  - termination of translation and, 272
  - translation elongation and, 271–272
  - in vitro* self-assembly, 266
  - in vitro* translation, 94, 95*f*
- Ribothymidine, 214*f*
- Ribozymes, 214
- Ribulose-1,5-bisphosphate, 445*f*

- Ribulose-1,5-bisphosphate carboxylase/oxygenase (rubisco), 446
- Ribulose-5-phosphate, 445*f*
- Rickettsia prowazekii*, 430
- rII* Gene, 94
- RISC. *See* RNA-induced silencing complex
- Ritovavir, 286
- RNA. *See* Ribonucleic acid
- RNA editing, 225–226
- RNA endonuclease, 208, 209*f*
- RNA helicase, 348
- RNA interference (RNAi)
- as an experimental tool to inhibit gene expression, 131
  - genome-wide screens of gene function and, 324–325
  - miRNAs and translational repression, 144, 258–259, 274–276
- RNA polymerase(s)
- bacterial, 200, 201–202
  - basic model of gene expression, 96
  - catabolite repressor protein and, 234
  - chloroplast genome and, 446
  - defined, 93
  - differences with DNA polymerases, 163–164
  - primase, 164–165
  - regulation of transcriptional elongation, 246–248
  - transcription hubs and, 355, 356
  - transcription of ribosomal RNA genes, 204, 208, 210, 211*f*, 357, 359
- See also* Eukaryotic RNA polymerases; specific RNA polymerases
- RNA polymerase I, 204, 208, 210
- RNA polymerase II
- chromatin remodeling factors and, 254
  - C-terminal domain, 207, 208, 216, 222, 246, 247*f*
  - enhancer RNAs and, 259, 260
  - general transcription factors and transcription by, 204–208, 209*f*
  - mRNA processing and, 216
  - promoter elements, 236
  - regulation of transcriptional elongation, 246–248
  - structure, 205*f*
  - transcription hubs and, 356
  - transcription of miRNAs, 275
  - transcription of rRNA genes, 357, 359
- RNA polymerase III, 204, 210, 211*f*
- RNA primers, 164–166
- RNA processing
- alternative splicing, 222–223, 225
  - overview, 212
  - processing of mRNA in eukaryotes, 215–217
  - processing of rRNAs and tRNAs, 212–215
  - RNA degradation, 226–227
  - RNA editing, 225–226
  - splicing mechanisms, 217–222
- RNA splicing
- alternative splicing, 142, 222–223, 225
  - defined, 137
  - discovery of introns and, 137–138, 139–140
  - Duchenne muscular dystrophy and splicing therapy, 224
  - mechanisms in, 217–222
  - in mRNA processing, 215
  - splicing components in nuclear speckles, 362
  - in tRNA processing, 215
- RNA synthesis
- introduction, 199
  - transcription in bacteria, 199–203
  - transcription in eukaryotes, 204–211
- RNA viruses, 23*f*; 97–99, 666*t*
- RNA world, 3, 4
- RNA-binding proteins, 297
- RNAcentral Consortium, 146
- RNAcentral database, 146
- RNA-dependent RNA polymerase, 286
- RNA-directed RNA synthesis, 97
- RNA–DNA hybrids, 137–138, 139
- RNAi. *See* RNA interference
- RNA-induced silencing complex (RISC), 131, 144, 275
- RNase, 106, 214
- RNA-seq, 315, 316, 321, 327
- Roberts, Richard, 137, 139*f*
- Rodbell, Martin, 571
- Roeder, Robert, 205
- Rotenone, 425
- Rothman, James, 396
- Rough endoplasmic reticulum
- animal and plant cells, 7*f*
  - insertion of transmembrane proteins into, 373–379
  - nuclear membrane and, 336–337
  - protein folding and processing in, 379–381
  - protein secretory pathway and, 366–368
  - quality control of protein folding in, 381–385
  - structure and functions of, 8, 366
  - subcellular fractionation, 34, 36
  - targeting proteins to, 368–373
- Rous, Peyton, 22, 23, 668
- Rous sarcoma virus (RSV)
- discovery of proto-oncogenes and, 670
  - discovery of tyrosine kinases and, 294, 300
  - DNA provirus hypothesis and, 98–99
  - sarcomas and early studies of, 22
  - src* oncogene, 668
  - Src protein, 294, 579, 580
  - tyrosine kinases and, 578, 668
- RPA protein, 168, 183, 184*f*, 612
- Rpd3p corepressor, 252
- rRNA. *See* Ribosomal RNA
- RSV. *See* Rous sarcoma virus
- Rubisco, 446
- Ruderman, Joan, 607, 608
- Ryanodine receptors, 520, 521*f*
- S**
- S phase
- Cdk inhibitors, 610
  - definition and overview of, 599
  - DNA damage checkpoint, 603, 615–616
  - identification of, 600
  - regulation of DNA replication, 612–615
- S region of antibody genes, 195, 196
- S6 kinase, 589
- Sabatini, David, 368, 369
- Saccharomyces cerevisiae*
- an experimental model, 16
  - Cdc28 protein and cell cycle regulation, 604, 606
  - centromeric DNA sequences, 157
  - characteristics of introns and exons in, 140
  - chromosome number, 153*t*
  - description of, 10
  - genome size, 11*t*, 16, 153*t*
  - MAP kinase cascades, 585
  - origins of replication, 173–175
  - START and cell cycle regulation, 600–601
- Salamanders, 136*f*
- Salts, 42
- SAM complex, 435–436
- Sanger, Frederick, 61, 310
- Sanger sequencing, 106–107
- Sanofi pharmaceutical company, 330
- Sarcomas, 22, 661
- Harvey sarcoma virus, 672
  - Kaposi's sarcoma, 666*t*
- Sarcomeres
- desmin and, 497
  - neurotransmission at neuromuscular junctions and, 520, 521*f*
  - sarcoplasmic reticulum, 473, 520, 521*f*
  - sliding filament model of muscle contraction, 470–473
  - structure and organization, 469–470
- Sarcoplasmic reticulum, 473, 520, 521*f*
- Sarepta Therapeutics, 224
- SARS. *See* Severe acute respiratory syndrome
- SARS-CoV-2 virus
- description of and the COVID-19 pandemic, 331
  - lipid membrane of, 22
  - protease inhibitors and, 286
  - RNA genome, 97
  - structure, 23*f*
  - synthetic mRNA vaccines, 330, 331–332
- Satellite cells, 636–637
- $\alpha$ -Satellite DNA, 147, 157
- Saturated fatty acids, 51
- Scaffold proteins, 585–586
- Scanning electron microscopy, 33, 34*f*
- scaRNAs. *See* Small Cajal body–specific RNAs
- Scemblix (asciminib), 689*t*, 690
- SCF<sup>SKP2</sup> ubiquitin ligase, 612, 615
- Schatz, Gottfried, 433
- Schekman, Randy, 396
- Schizosaccharomyces pombe*, 602, 606
- Schleiden, Matthias, 25
- Schreiber, Stuart, 251, 252
- Schwann, Theodor, 25
- Sclerenchyma, 12
- Scramblase, 651
- Scrapie, 282–283
- scRNAs. *See* Small conditional RNAs

- Scurvy, 547
- SDS. *See* Sodium dodecyl sulfate
- SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 115–116
- Sea urchins
  - gene regulatory networks, 327–328
  - identification of cyclins, 606–608
- Sebaceous glands, 636
- Sec pathway, 448*f*, 449
- Sec61 proteins, 372, 375
- SecA protein, 448*f*, 449
- Second filial (F<sub>2</sub>) generation, 85–86, 87*f*
- Second law of thermodynamics, 44
- Second messengers, 574–575, 576
- Secondary response genes, 585
- Secondary structure of proteins, 64
- $\gamma$ -Secretase, 592, 593*f*
- Secretory granules, 393–394
- Secretory pathway
  - discovery and overview of, 366–368
  - export of proteins and lipids from the endoplasmic reticulum, 386–388
  - lysosome formation, 404, 405*f*
  - mechanism of vesicular transport, 396–401
  - protein sorting and export from the Golgi apparatus, 393–396
  - regulated secretory pathway, 393–394
  - targeting proteins to the rough ER, 368–373
  - transmembrane proteins, 373–379
- Securin, 624–625
- Sedimentation, 34
- Sefton, Bartholomew, 294, 300
- Segregation, of genes, 86, 87*f*
- Sela, Michael, 63–64
- Selectins, 554–555, 556
- Selective permeability, 79–80
- Selectivity factor 1 (SL1), 208, 210*f*
- Selenocysteine, 267
- Self-replication, nucleic acids and the origin of life, 3, 4
- Self-splicing by RNA, 219, 221–222
- Semiconservative replication, 90–91
- Senile systemic amyloidosis, 281*t*
- Separase, 624–625
- Sequencing by synthesis, 311, 312*f*, 313
- Serine
  - genetic code, 94*f*, 95*f*
  - glycerol phospholipids and, 52
  - phosphorylation, 74
  - sphingomyelin and, 53
  - structure and properties of, 59*f*, 60
- Serine proteases, 70–71
- Serine/threonine kinases, 291–292, 293*f*
  - See also* Tyrosine kinases
- Serotonin, 225–226
- Serum amyloid A protein, 281*t*
- Serum response element (SRE), 585
- Serum response factor (SRF), 241, 585
- Severe acute respiratory syndrome (SARS), 331
- Sex determination, alternative splicing in *Drosophila* and, 223
- Sex steroids, 565
- Sgo1-PP2A phosphatase complex, 620
- Sgt2 chaperone protein, 378, 379
- SH2 domains, 579, 580, 581, 584, 586
- Sharp, Phillip, 137, 139–140, 244
- Sheep, cloned, 642, 643
- Sheetz, Michael, 484–485
- Shelterin, 159
- Shimomura, Osamu, 28
- Shine, John, 268
- Shine-Dalgarno sequence, 268, 269*f*
- Short interfering RNAs (siRNAs)
  - description of, 274–275
  - RNA interference and, 131, 274, 275
- Short interspersed elements (SINEs), 147–149
- Short noncoding RNAs, 145*t*
- Shotak, Kevan, 692
- Shotgun mass spectrometry, 317–318
- Sickle-cell anemia, 92
- Signal hypothesis, 368–370
- Signal peptidase, 373, 375
- Signal recognition particle (SRP)
  - cotranslational insertion of transmembrane proteins and, 375, 376*f*
  - cotranslational pathway and, 370, 371*f*, 372, 373
- Signal sequences
  - cotranslational pathway and, 370, 371*f*, 372–373
  - discovery and description of, 368–370, 371*f*
  - internal transmembrane sequences, 375–377
  - protein export from the Golgi apparatus and, 395
  - of resident ER proteins, 387–388
  - translocation of chloroplast proteins and, 448
  - transmembrane sequences of proteins destined for the nuclear envelope, 379
- Signal transduction pathways
  - analysis of, 326–327
  - cAMP pathway, 574–577
  - cancer cells and cell proliferation, 664
  - cancer genomics and, 686
  - crossstalk and signaling networks, 595
  - feedback loops and signaling dynamics, 594–595
  - G proteins and G protein-coupled receptors, 570–573
  - MAP kinase pathways, 582–586
  - mTOR pathway, 588–590
  - NF- $\kappa$ B signaling, 591–592
  - overview and description of, 299–300
  - PI 3-kinase/Akt pathway, 586–588
  - proto-oncogenes and, 669
  - ras* oncogenes and, 583
  - regulation of apoptosis, 653–656
  - signal transduction defined, 570
  - TFG- $\beta$ /Smad pathway, 591
  - tyrosine kinases and, 578–581
  - Wnt and Notch pathways, 592–593
- Signaling molecules
  - importance and overview of, 563–564
  - lipids, 53
  - modes of cell–cell signaling, 564–565
  - peptide hormones and growth factors, 568–569
  - small signaling molecules, 567–568
  - steroid hormones and the nuclear receptor superfamily, 565–566, 567*f*
- Signaling networks, 595
- Simian virus 40 (SV40)
  - DNA polymerases and DNA replication, 167
  - enhancers, 237
  - Mercel cell carcinoma and, 666*t*
  - origin of replication, 172
  - specificity protein 1, 243, 244, 245
  - T antigen nuclear localization signal, 343, 344
- Simple sugars, 49–50, 51
- Simple-sequence repeats, 147, 157, 159
- SINEs. *See* Short interspersed elements
- Singer, Jonathan, 77, 78, 506, 507
- Single bonds, 41
- Single-stranded DNA-binding proteins, 168, 172
- siRNAs. *See* Short interfering RNAs
- SIRT2* gene, 241
- Sister chromatids, 156*f*, 157, 620–621, 623–625
- Skeletal muscle
  - adult stem cells, 636–637
  - sarcomeres and muscle contraction, 470–473
  - structure and organization of sarcomeres, 469–470
- Skin
  - gap junction mutations and, 558*t*
  - keratins and, 497–498
  - stem cells of, 636, 637
- Skin fibroblasts
  - cell cycle, 600
  - proliferation of, 631
- Skloot, Rebecca, 21
- SL1, 208, 210*f*
- SLE. *See* Systemic lupus erythematosus
- Sliding filament model of muscle contraction, 470–473
- Sliding-clamp proteins, 167, 169*f*
- Sm antigen, 220
- Smad transcription factor family, 591
- Smad* tumor suppressor genes, 683
- Small Cajal body–specific RNAs (scaRNAs), 360
- Small conditional RNAs (scRNAs), 204
- Small cytoplasmic RNA, 370
- Small molecule transport
  - active transport by ATP hydrolysis, 525–528
  - active transport by ion gradients, 528–530
  - facilitated diffusion and carrier proteins, 514, 515*f*
  - ion channels, 514, 515*f*; 516–525 (*see also* Ion channels)
  - overview, 513

- Small nuclear ribonucleoprotein particles (snRNPs)  
 assembly and recycling in Cajal bodies, 360–361  
 snRNAs and the formation of, 348*f*, 349, 360  
 spliceosomes and RNA splicing, 218–221, 222  
 transfer to nuclear speckles, 362
- Small nuclear RNAs (snRNAs)  
 discovery and importance of, 220–221  
 formation of snRNPs and, 348*f*, 349, 360  
 nucleocytoplasmic transport, 348–349  
 RNA polymerases and, 204  
 RNA splicing and, 218–219, 220–221, 222  
 transcription of, 204, 210, 211*f*
- Small nucleolar RNAs (snoRNAs)  
 functions of, 359  
 localized in the nucleus, 348  
 nested genes and, 141  
 number in the nucleolus, 359  
 processing of, 212–213
- Small signaling molecules, 567–568
- SMC proteins, 620
- Smell. *See* Odor detection
- Smith, Alan, 343, 344
- Smith, Dennis, 604, 605
- Smooth endoplasmic reticulum  
 animal and plant cells, 7*f*  
 functions of, 8, 366  
 lipid synthesis and metabolism, 385–386  
 plasmodesmata, 559, 560*f*  
 subcellular fractionation, 34, 36
- Smooth muscle cells, 469, 632
- SNAP transcription factor, 210, 211*f*
- SNAREs, 401, 519
- snoRNAs. *See* Small nucleolar RNAs
- snoRNPs, 212–213
- snRNAs. *See* Small nuclear RNAs
- snRNPs. *See* Small nuclear ribonucleoprotein particles
- Snurportin, 347*t*, 349
- Sodium channels  
 ligand-gated, 520  
 odor detection and, 576  
*See also* Voltage-gated sodium channels
- Sodium chloride, 42
- Sodium dodecyl sulfate (SDS), 115
- Sodium ions  
 action potentials and, 520, 522, 523*f*  
 active transport by sodium ion gradients, 529–530  
 active transport by the Na<sup>+</sup>-K<sup>+</sup> pump and, 525–527  
 intracellular and extracellular concentrations in mammalian cells, 517*t*  
 ionic bonds, 42  
 in neurotransmission, 519, 520  
 resting membrane potential and, 517–518
- Soft keratins, 493
- Somatic cells  
 somatic cell nuclear transfer, 642–643  
 transdifferentiation, 645–646
- Somatic hypermutation, 195–196
- Sotorasib (Lumakras), 689*t*, 692
- Southern, E. M., 112
- Southern blotting, 112, 113*f*
- Sox2, 643
- Specificity protein 1 (Sp1), 243, 244, 245
- Speckles, 357*t*, 362
- Spectrin, 463–464, 508, 512
- Sphingolipids, 436, 505
- Sphingomyelin  
 in cell membranes, 503, 505  
 lipid rafts, 505  
 in plasma membranes, 76  
 structure, 52–53, 504*f*  
 synthesis in the Golgi apparatus, 392–393  
 updated version of the fluid mosaic model, 511*f*, 512
- Spike proteins, 23*f*, 331, 332
- Spinal cord injury, 640
- Spindle assembly checkpoint, 603, 623–625
- Spindle microtubules  
 attachment of chromosomes to, 617, 618, 619, 623  
 cell plate formation and, 626  
 chromosome alignment on the metaphase plate and, 623  
 separation of chromosomes in anaphase and, 625
- Spleen, 403
- Spliceosomes, 218–219, 222
- Splicing, 137  
*See also* RNA splicing
- Splicing activators, 223
- Splicing enhancers, 223, 224
- Splicing factors, 142, 362
- Splicing therapy, 224
- Spongiform encephalopathies, 281*t*, 282–283
- SPP. *See* Stromal processing peptidase
- SR protein family, 223
- src oncogene, 668, 669, 670, 675
- Src protein family  
 as lipid-anchored proteins, 509*f*, 510  
 role in cell signaling, 580–581  
 Rous sarcoma virus and, 294, 579, 580
- SRE. *See* Serum response element
- SRE. *See* Serum response factor
- SRP. *See* Signal recognition particle
- SRP receptor, 371*f*, 372, 376*f*, 377*f*
- SRP RNA, 370
- Stability genes, 685, 688
- Stably transfected cells, 121
- Stahl, Frank, 91
- Starch, 50–51
- START, 600–601, 606, 610
- Start codon  
 in eukaryotic and prokaryotic mRNAs, 268  
 initiation of translation and, 96, 268, 269, 270, 271*f*
- STAT proteins, 580
- Stearate, 51*f*
- Stehelin, Dominique, 670
- Steitz, Joan, 220–221
- Steitz, Thomas, 267
- Stem cells  
 cancer stem cells, 665  
 definition and properties of, 632–633  
 embryonic stem cells, 639–642  
 identification and examples of, 633–637  
 induced pluripotent stem cells, 642, 643–645  
 medical applications, 637–638  
 niches, 637
- Stereocilia, 465
- Steroid hormones  
 nuclear receptor superfamily and, 565–566, 567*f*  
 overview and description of, 565  
 regulation of transcription factors, 289  
 structure and function, 53  
 synthesis in the smooth ER, 386
- Stochastic optical reconstruction microscopy (STORM), 31, 32*f*
- Stomach cancer, 666
- Stomach ulcers, 666
- Stop codons  
 alternative splicing of the *transformer* gene and, 223  
 in eukaryotic and prokaryotic mRNAs, 268  
 genetic code and, 95*f*  
 identification of protein-coding genes and, 305  
 selenocysteine and, 267  
 termination of translation and, 96*f*, 97, 272
- STORM (stochastic optical reconstruction microscopy), 31, 32*f*
- Stress fibers, 464, 468, 474
- Stroma  
 ATP production in mitochondria and chloroplasts compared, 441*f*  
 dark reactions of photosynthesis, 445–446  
 defined, 439  
 function of, 440  
 light reactions of photosynthesis, 443, 444  
 translocation of chloroplast proteins and, 447, 448–449
- Stromal processing peptidase (SPP), 447
- Structural maintenance of chromatin (SMC) proteins, 620
- STT1 and 2 proteins, 448–449
- Subcellular fractionation, 34–36
- Substrate-level phosphorylation, 423
- Substrates  
 competitive inhibition of enzymes, 73  
 defined, 68  
 enzymatic activity of enzymes, 68–69  
 mechanisms of enzymatic catalysis, 69–71
- Succinate, 420*f*
- Succinate dehydrogenase, 420*f*
- Succinate reductase (complex II), 426
- Succinyl-CoA, 420*f*
- Succinyl-CoA synthetase, 420*f*
- Südhof, Thomas, 396
- Sugars  
 in nucleic acids, 54  
*See also* Glucose
- SUN proteins, 339*f*

- Supernatant, 34, 35*f*  
 Superoxide dismutase, 281*t*  
 Super-resolution microscopy, 31–32  
 Sutherland, Earl, Jr., 574  
 SV40. *See* Simian virus 40  
 Sweet wormwood, 330  
 Switch (S) region of antibody genes, 195, 196  
 SXL protein, 223  
 Synapses, 516, 517*f*; 519–520  
 Synaptic cleft, 516, 517*f*  
 Synaptic vesicles, 517*f*; 519  
 Synaptotagmin, 519  
 Synthesis-dependent strand annealing, 189*f*, 190  
 Synthetic biology  
   creation of a fully synthetic cell and, 330–331  
   definition and description of, 328–330  
   practical applications and COVID-19 mRNA vaccines, 330, 331–332  
 Synthetic cells, 330–331  
 Systemic amyloidoses, 281*t*, 282  
 Systemic lupus erythematosus (SLE), 220  
 Systems biology  
   analysis of gene regulation, 325–326  
   analysis of networks, 326–328  
   overview, 323–324  
   synthetic biology, 328–332  
   systematic screens of gene function, 324–325  
 Szostak, Jack, 176, 177
- T**
- T antigen, 172, 343, 344  
 T lymphocytes (T cells)  
   autocrine signaling and, 564  
   CAR-T cell therapy, 694–695  
   formation of, 634*f*  
   immune checkpoint inhibitors and, 693–694  
   T-cell receptors and programmed DNA rearrangements, 191, 193–194  
 T4 bacterial virus, 93, 94  
 TADs. *See* Topologically associated domains  
 TAFs. *See* TBP-associated factors  
 Tail-anchored proteins, 377–379  
 TAK1 protein, 586*f*  
 Takahashi, Kazutoshi, 643–644  
 Talin, 464, 553*f*  
 Tamkun, John W., 551–552  
 Tandem mass spectrometry, 317, 318*f*  
 Taq polymerase, 111*f*  
 Tarceva (erlotinib), 689*t*, 690–691  
 Tat pathway. *See* Twin-arginine translocation pathway  
 TATA box, 205, 206*f*; 237  
 TATA-binding protein (TBP), 205, 206*f*  
 Tau protein  
   Alzheimer's disease and, 281*t*, 282, 283, 297, 481, 482  
   liquid–liquid phase separation, 297  
   microtubule-associated proteins and, 481, 482  
   neurodegenerative diseases associated with, 281*t*  
   neurofibrillary tangles and, 282, 283, 481  
 Tauopathies, 283  
 Taxol, 479  
 TBP. *See* TATA-binding protein  
 TBP-associated factors (TAFs), 205, 206*f*; 247*f*  
 T-cell receptors, 191, 193–194, 693, 694  
 Tcf transcription factors, 592, 676*f*; 677  
 TDP-43 protein, 281*t*  
 Tecentriq (atezolizumab), 694*t*  
 Tel transcription factor, 690  
 Telomerase  
   Cajal bodies and the assembly of, 361  
   cancer cells and, 665  
   definition and functions of, 159, 176–178  
 Telomeres  
   cancer cells and, 665  
   chromosome organization and, 351  
   definition and description of, 158–159, 176–178  
 Telophase  
   chromosomes in, 156*f*  
   overview, 617, 618*f*; 619  
   plant cells, 626  
 Tel/PDGFR fusion protein, 674–675  
 Temin, Howard, 97, 98–99  
 Tendons, 546–547  
 Teratocarcinomas, 641  
 Terminal deoxynucleotidyl transferase, 194  
 Terminal web, 466  
 Termination  
   of bacterial RNA synthesis, 202–203  
   of RNA polymerase II transcription, 208, 209*f*  
 Tertiary structure of proteins, 64–66  
 Testes, steroid-producing cells in, 386  
 Testosterone, 53*f*; 565  
 TET family enzymes, 258  
 Tethering factors, 401  
 Tetrahydrofoate, 73*t*  
 Tetrahymena  
   catalytic activity of the rRNA ribozyme, 267  
   histone acetyltransferase, 251–252  
   self-splicing of rRNA, 219, 221  
   telomerase, 176, 177  
   telomeres, 158–159  
 Tezacaftor, 529  
 TFG- $\beta$ /Smad pathway, 591  
 TFIIB, 205, 206*f*; 245  
 TFIIB recognition elements (BRE), 205, 206*f*  
 TFIID, 205, 206*f*; 245, 251  
 TFIIE, 205, 206*f*  
 TFIIH, 183, 184*f*; 205, 206*f*; 207–208, 246, 247*f*  
 TFIIIA, 210, 211*f*  
 TFIIB, 210, 211*f*  
 TFIIC, 210, 211*f*  
 TGF- $\beta$ . *See* Transforming growth factor  $\beta$   
 $\beta$ -Thalassemia, 222  
 Therapeutic cloning, 643  
 Therapeutic drugs, synthetic biology and, 330
- Thermodynamics  
   fluid mosaic model of membranes, 78  
   introduction, 40–41  
   laws of, 44  
   thermodynamic hypothesis of protein folding, 64  
 Thermogenin, 427  
 Thermus aquaticus, 111  
 Thiamine (vitamin B<sub>1</sub>), 73*t*  
 Thiamine pyrophosphate, 73*t*  
 Thiogalactoside, 230  
 3C. *See* Chromosome conformation capture  
 3' to 5' Exonucleases, 166, 171  
 3' Untranslated region  
   basic model of gene expression, 96*f*; 97  
   miRNA-mediated translational repression, 275  
   in mRNA structure, 268  
   translational repressors and, 274  
 Threonine  
   genetic code, 94*f*; 95*f*  
   isoleucine synthesis and, 74  
   phosphorylation, 74  
   structure and properties of, 59*f*; 60  
 Threonine deaminase, 74  
 Threshold potential, 522, 523*f*  
 Thrombin, 70  
 Thylakoid lumen  
   chemiosmotic generation of ATP and, 440, 441*f*  
   defined, 439  
   light reactions of photosynthesis, 443  
   translocation of chloroplast proteins and, 448–449  
 Thylakoid membrane  
   electron transport chain and ATP production, 440, 441  
   electron transport chain and the light reactions of photosynthesis, 442–444  
   photosystems and, 441  
   structure, 439  
   translocation of proteins, 448–449  
 Thylakoid processing protease (TPP), 448*f*, 449  
 Thylakoids, 439  
   *See also* Thylakoid lumen; Thylakoid membrane  
 Thymidine, 164  
 Thymidine kinase, 236–237  
 Thymine  
   complementary base pairing and, 56, 58*f*  
   definition and structure of, 54  
   dideoxynucleotide in DNA sequencing, 106–107  
   DNA structure, 89–90  
   genetic code, 94*f*  
   UV light and thymine dimers, 180*f*; 181*f*  
 Thyroid hormone, 565, 566, 567*f*; 677  
 Thyroid hormone receptor, 566, 567*f*; 677  
 Tic complex, 447  
 TIF-IA. *See* Transcription initiation factor IA  
 Tight junctions, 510, 511*f*; 556–557  
 Till, James, 633

- Tim complexes, 433–434, 435  
 Tim9-Tim10 chaperones, 434*f*, 435  
 Tjian, Robert, 243, 244  
 TNF. *See* Tumor necrosis factor  
 Toad genome, 136*f*  
 Tobacco mosaic virus, 97  
 Tobacco smoke, 666  
 Toc complex, 446, 447  
 Toll-like receptors, 592  
 Tom complex, 433, 434, 435, 436  
 Tonegawa, Susumu, 191, 192  
 Topoisomerases, 168–169  
 Topologically associated domains (TADs), 239–240, 353–354  
 TPP. *See* Thylakoid processing protease  
 Tracheids, 13*f*  
 Trametinib (Mekinist), 689*t*  
 trans Golgi compartment, 389, 390*f*  
 trans-Golgi network  
   assembly of clathrin-coated vesicles, 400–401  
   autophagosome formation and, 407  
   description and functions of, 389, 390*f*  
   lysosome formation and, 404, 405*f*  
   protein glycosylation and, 391  
   protein sorting and export from the Golgi apparatus, 393–395, 396  
   transport by coated vesicles and, 400  
 Transacetylase, 230–231, 232*f*  
 Trans-acting factors, 233  
 Transcription  
   in bacteria, 199–203  
   basic model of gene expression, 96  
   central dogma of molecular biology, 93  
   defined, 3–4  
   in eukaryotes, 204–211  
   Polycomb bodies and transcriptional repression, 360, 361*f*  
 Transcription factors  
   binding sites, 240–243  
   *cis*-acting regulatory sequences, 236–237  
   defined, 205  
   general transcription factors, 205–208  
   genome-wide analysis of transcription factor binding sites, 326  
   growth factor receptors coupled to, 591–593  
   induced pluripotent stem cells and, 643  
   methods of isolating, 243–245  
   nuclear receptor superfamily, 565–566, 567*f*  
   number in the human genome, 245  
   oncogenic activity, 675, 677  
   overview, 235–236  
   regulation by small molecules, 289  
   regulation by the MAP ERK kinase pathway, 585  
   regulation by the PI 3-kinase/Akt pathway, 587, 588*f*  
   regulation of elongation, 246–248  
   regulation of import into the nucleus, 349–350  
   repressors and transcriptional activators, 245, 246*f*  
   *Smad* tumor suppressor genes and, 683  
   in transcription by RNA polymerases I and III, 208, 210, 211*f*  
   transdifferentiation of somatic cells and, 645–646  
 Transcription hubs, 355–356  
 Transcription initiation factor IA (TIF-IA), 210  
 Transcriptional activators  
   chromatin remodeling factors and, 254  
   definition and function of, 245, 246*f*  
   histone acetylation and, 251–252  
 Transcriptional regulation  
   chromatin and epigenetics, 248–260  
   chromatin remodeling factors, 254  
   concurrent regulatory mechanisms, 234–235  
   DNA methylation, 256–258  
   in *E. coli*, 230–235  
   histone modifications and, 249–253  
   negative control of, 231–233  
   noncoding RNAs, 258–260  
   oncogenes and, 675, 677  
   positive control of, 233–234  
   regulation of elongation, 246–248  
   transcription factors in eukaryotes, 235–248 (*see also* Transcription factors)  
   tumor suppressor genes and, 683  
 Transcriptomes, 314–316  
 Transdifferentiation, 645–646  
 Transfection, 119–122  
 Transfer RNA (tRNA)  
   basic model of gene expression, 96*f*, 97  
   chloroplast genome and, 446  
   defined, 93  
   degradation, 226  
   encoded by the mitochondrial genome, 430–431  
   export from the nucleus, 348  
   formation of polypeptides and, 60, 61*f*  
   functions of, 53–54, 93, 94*f*  
   genetic code, 93–95  
   processing of, 214–215  
   ribosome binding sites for, 271–272  
   RNA polymerases that transcribe the genes of, 204  
   structure, 57*f*, 264  
   transcription of, 210, 211*f*  
   translation of mRNA and, 264, 265*f*, 269, 270, 271–272  
 Transformation  
   *E. coli* transformation in molecular cloning, 103–105, 106  
   in studies identifying DNA as the genetic material, 88  
 Transformer (*tra*) gene, 223  
 Transforming growth factor  $\beta$  (TGF- $\beta$ ), 591, 637, 683  
 Transforming growth factor  $\beta$  (TGF- $\beta$ ) receptor, 683  
 Transgenic mice  
   keratins and skin development, 497–498  
   methods of producing, 121–122  
 Transient expression (transient transfection), 119  
 Transit peptides, 446  
 Transit-amplifying cells, 633, 635, 636  
 Transition state, 68*f*, 69, 70  
 Translation  
   basic model of gene expression, 96–97  
   central dogma of molecular biology, 93  
   defined, 4  
   formation of polypeptides, 60, 61*f*  
   functions of tRNA, 264, 265*f*; 269, 270, 271–272  
   initiation of, 267–271  
   overview, 263–264  
   process and stages of, 269–273  
   regulation of, 273–277  
   ribosome characteristics, 264, 266–267  
   RNA interference and translational repression, 144, 258–259, 274–276  
   in vitro translation, 94–95  
 Translational regulation  
   regulation of global translation, 276–277  
   repressor proteins, 273–274  
   translational repression by miRNA, 274–276  
 Translesion DNA synthesis, 185–187  
 Translocases, 433–434, 435–436  
 Translocations, 272, 672–673, 674*f*  
 Translocons  
   contraction sorting of secretory proteins to the ER, 371*f*; 372–373  
   defined, 372  
   import of chloroplast proteins and, 446, 447  
   insertion of transmembrane proteins and, 375, 376*f*  
   protein sorting and, 368*f*  
 Transmembrane domains  
   defined, 79  
   description of, 373–374  
   GPI-anchored proteins, 381  
   orientation of membrane proteins and, 374  
   tail-anchored proteins, 377, 378  
 Transmembrane proteins  
   definition and characteristics of, 79, 507  
   export from the endoplasmic reticulum to the Golgi apparatus, 387  
   export from the Golgi apparatus, 393, 394*f*  
   facilitated diffusion and, 514, 515*f*  
   insertion into the rough ER membrane, 373–379  
   plasma membrane domains and, 512  
   as transporters, 80  
   *See also* Integral membrane proteins  
 Transmission electron microscopy, 33  
 Transplantation therapy, 643  
 Transport vesicles  
   coat proteins and vesicle budding, 398–400  
   GTP-binding proteins in vesicle budding and cargo recruitment, 400–401  
   lysosome formation and, 404, 405*f*  
   mechanism of vesicular transport, 396–401  
   protein export from the Golgi apparatus, 393, 394*f*  
   protein movement through the Golgi apparatus and, 389–390

- secretory pathway (*see* Secretory pathway)  
vesicle docking and fusion, 401
- Transportin, 347*t*
- Transposable elements  
definition and description of, 147–148  
in disease and evolution, 148–149
- Transthyretin, 281*t*
- Trastuzumab (Herceptin), 689
- $\beta$ -TrCP ubiquitin ligase, 592
- Treadmilling, 460
- Triacylglycerols (triglycerides; fats), 51–52, 421
- Trichothiodystrophy, 182, 183
- Trikafta, 529
- Triose phosphate isomerase, 418*f*
- tRNA. *See* Transfer RNA
- Tropomyosin, 461, 464, 472, 473
- Troponin, 473
- Trypanosomes, 225
- Trypsin, 70, 71, 317
- Tryptophan, 59, 95*t*
- TSC protein, 588, 589, 595*f*
- Tsien, Roger, 28
- T-tubules, 520, 521*f*
- Tubulin  
definition and structure of, 476, 477*f*  
dynamic instability of microtubules and, 477–479  
formation of the mitotic spindle and, 622  
microtubule assembly by centrosomes and, 480  
overview, 458*f*  
polymerization to form microtubules, 476–477  
 $\gamma$ -tubulin ring complex, 480, 481
- Tumor initiation, 662
- Tumor necrosis factor (TNF), 592, 655–656
- Tumor progression, 662
- Tumor promoters, 666
- Tumor suppressor genes  
cancer genomics and, 685–686  
defined, 611  
functions of proteins encoded by, 683–685  
identification of, 680–683  
inherited cancer susceptibility and, 688  
overview, 679  
Rb protein and, 611–612
- Tumor viruses  
human cancer and, 22, 666–667  
oncogenes and, 667  
proto-oncogenes and, 669–671  
retroviral oncogenes, 668–669
- Tumors  
definition and types of, 660–661  
development of cancer and, 662  
oncogenes in human cancer and, 671–673, 674  
*See also* Cancer
- Tunneling nanotubes, 560
- Turgor pressure, 544–545
- Twin-arginine translocation (Tat) pathway, 448–449
- Type 1 diabetes, 640
- Type 2 diabetes, 281–282
- Type I collagen, 547
- Type I topoisomerases, 168
- Type II topoisomerases, 168–169
- Type IV collagen, 548, 551
- Tyrosine  
genetic code, 94*f*, 95*f*  
phosphorylation, 74  
structure and properties of, 59*f*, 60
- Tyrosine kinase inhibitors, 689–691
- Tyrosine kinases  
cancer and, 294–295, 300, 578, 668  
definition and overview of, 291–292, 293*f*  
discovery of, 294–295, 668  
nonreceptor tyrosine kinases, 578, 579–581  
as oncogene proteins, 674–675  
receptor tyrosine kinases, 578–579, 580*f*  
(*see also* Receptor tyrosine kinases)
- U**
- U2AF splicing factor, 222, 223
- U4/U6-U5 tri-snRNP complex, 360
- UAA stop codon, 272
- UAG stop codon, 272
- UBF. *See* Upstream binding factor
- Ubiquinol, 425–426
- Ubiquinone, 425–426
- Ubiquitin  
histone modification and, 252, 253  
protein degradation, 297–299  
protein regulation and, 295
- Ubiquitin ligase  
E3 enzyme, 298, 349, 382*f*, 383  
MDM2 ubiquitin ligase, 616  
SCF<sup>SKP2</sup> ubiquitin ligase, 612, 615  
 $\beta$ -TrCP ubiquitin ligase, 592
- Ubiquitin-activating enzyme (E1), 298
- Ubiquitination (ubiquitylation)  
of cyclin B, 298–299, 608–609  
of I $\kappa$ B proteins, 592  
protein degradation and, 297–299
- Ubiquitin-conjugating enzyme (E2), 297
- Ubiquitin-proteasome pathway  
ER-associated degradation and, 381, 382*f*, 383  
protein degradation, 297–299
- UCE. *See* Upstream control element
- UDP-glucose, 50
- UDP-glucose:glycoprotein glucosyltransferase (UGGT), 382*f*, 383
- UGA stop codon, 272
- UGGT. *See* UDP-glucose:glycoprotein glucosyltransferase
- UHRF1, 256–257
- Ultracentrifuge, 34
- Ultraviolet radiation  
cancer and, 666  
damage to DNA, 180*f*, 181  
direct reversal of DNA damage from, 181  
nucleotide-excision repair of DNA damage from, 182–184
- UMP. *See* Uridine 5'-monophosphate
- Unconventional myosins, 474–476
- Unfolded protein response, 383–385
- Unicellular eukaryotes, 11*t*
- Unsaturated fatty acids, 51, 76, 505
- Upstream binding factor (UBF), 208, 210*f*
- Upstream control element (UCE), 208, 210*f*
- Uracil  
activation-induced deaminase and, 196  
base pairing with adenine, 56, 57*f*, 58*f*  
base-excision repair of uracil-containing DNA, 181–182  
formation by cytosine deamination, 180*f*  
genetic code, 95  
RNA and, 54, 57*f*, 93
- Urea, 3*f*
- Uridine  
modifications in tRNAs, 214*f*  
nonstandard codon–anticodon base pairing and, 264, 265*f*  
RNA editing and, 225  
structure, 54*f*  
uridine isomerization, 213
- Uridine 5'-monophosphate (UMP), 54*f*
- Uridine triphosphate (UTP), 50
- U.S. National Institutes of Health, 306
- U.S. National Research Council, 306
- UTP. *See* Uridine triphosphate
- UvrABC protein complex, 182
- V**
- V region of antibody genes, 192, 193*f*, 195
- Vaccines, COVID-19 and, 331–332
- Vacuoles, 7*f*, 8
- Vale, Ronald, 484–485
- Valine, 59, 94*f*, 95*f*
- van der Waals interactions, 43–44
- Varmus, Harold, 669, 670
- Vascular endothelial growth factor (VEGF), 631–632
- Vascular tissue, 12, 13*f*
- Vectors  
in cDNA cloning, 105*f*, 106  
expression vectors, 108, 119, 120*f*, 121  
in molecular cloning, 101–105
- VEGF. *See* Vascular endothelial growth factor
- Velocity centrifugation, 34, 36*f*
- Venclexta (venetoclax), 689*t*
- Venetoclax (Venclexta), 689*t*
- Venter, Craig, 306, 307, 314, 330
- Vertebrates, as experimental models, 18–19
- Vesicle budding  
GTP-binding proteins and, 400–401  
vesicle coat proteins and, 398–400
- Vesicle coat proteins, 398–400, 401
- Vesicular transport  
coat proteins and vesicle budding, 398–400  
export of proteins and lipids from the endoplasmic reticulum, 386–388  
GTP-binding proteins in vesicle budding and cargo recruitment, 400–401  
microtubules and motor proteins, 486  
overview and significance of, 396–397  
role in protein processing and sorting, 365  
vesicle docking and fusion, 401
- Vessel elements, 13*f*

- Villin, 466  
 Viltoso, 224  
 Vimentin, 493, 495, 497  
 Vinblastine, 478–479  
 Vincristine, 478–479  
 Vinculin, 464, 465, 553*f*  
 Viral oncogenes, 667  
 Viruses  
   cancer and, 22, 23  
   entry into the nucleus, 342  
   as experimental models, 21–23  
   inhibition of host cell apoptosis, 653  
   internal ribosome entry sites, 269, 271  
   origins of replication, 172  
   tumor viruses, 666–667 (*see also* Tumor viruses)  
   as vectors in gene transfer, 121  
   *See also* specific viruses and virus types  
 Vitamin A, 565  
 Vitamin B<sub>1</sub>, 73*t*  
 Vitamin B<sub>2</sub>, 73*t*  
 Vitamin B<sub>6</sub>, 73*t*  
 Vitamin C, 547  
 Vitamin D<sub>3</sub>, 565  
 Vitamins, 72, 73*t*  
 Vogt, Peter, 668, 670  
 Vohwinkel syndrome, 558*t*  
 Voltage-gated calcium channels, 519  
 Voltage-gated ion channels  
   action potentials and, 520, 522, 523*f*  
   defined, 516  
   in neurotransmission, 516, 517*f*, 519, 520, 521*f*  
   selectivity of, 522, 524–525  
 Voltage-gated potassium channels  
   action potentials and, 520, 522, 523*f*  
   selectivity of, 522, 524–525  
 Voltage-gated sodium channels  
   action potentials and, 520, 522, 523*f*  
   neurotransmission at neuromuscular junctions, 520, 521*f*  
   selectivity of, 522, 524
- Volvox*, 12  
*Volvox africanus*, 11*t*  
 Vyondys 53, 224
- W**  
 Wallace, Douglas, 431  
 Warren, Robin, 666  
 WASP, 468*f*  
 Water  
   hydrogen bonds, 43  
   hydrophobic interactions, 43  
   a polar molecule, 41  
   production in oxidative phosphorylation, 425*f*, 426  
   splitting in photosynthesis, 5, 443, 445  
 Water channel proteins. *See* Aquaporins  
 Watson, James, 89–90, 163, 306, 314  
 Wee1 protein kinase, 608  
 Weinberg, Robert, 671  
 Weintraub, Harold, 645  
 Western blotting, 115–116  
 White, Frederick, Jr., 63–64  
 Whole-genome shotgun sequencing, 306  
 Wilkins, Maurice, 89  
 Wilmot, Ian, 642  
 Wnt pathway  
    $\beta$ -catenin and, 465, 592, 593*f*, 676–677  
   intestinal stem cells and, 637  
   oncogenic activity, 676–677  
   overview and description of, 592, 593*f*  
 Wnt proteins, 592, 593*f*  
 Wobble, 264, 265*f*, 431
- X**  
 X chromosome inactivation, 146, 259  
 Xalkori (crizotinib), 689*t*  
 XBP1 transcription factor, 383, 384*f*  
 Xeroderma pigmentosum (XP), 182–183, 685  
*Xist*, 146, 259  
 X-linked Emery–Dreifuss muscular dystrophy, 340  
 XP. *See* Xeroderma pigmentosum
- XPA–G proteins, 182–183  
 XPB protein, 207  
 XPD protein, 207  
 X-ray crystallography, 63, 89  
 XTP2B, 382*f*, 383  
 Xylem, 12, 13*f*
- Y**  
 Yamanaka, Shinya, 643–644  
 Yeast two-hybrid system, 319, 320  
 Yeasts  
   cell cycle and cell cycle regulation, 599, 600–601, 602  
   characteristics of introns and exons in, 140  
   chromosome number, 153*t*  
   cyclins and cyclin-dependent kinases, 609*f*  
   description of, 10  
   evolution of cells, 9*f*  
   as experimental models, 15–16  
   Gcn5p and histone acetylation, 251–252  
   genome size, 11*t*, 136*f*, 153*t*  
   noncoding RNAs and organismal complexity, 308*f*  
   nucleotide-excision repair, 182  
   origins of replication, 173–175  
   protein-coding sequences, 305  
   protein-coding sequences versus long noncoding RNAs, 146*t*  
   regulation of transcription factor import into the nucleus, 349–350  
   structure of RNA polymerase II, 205*f*  
   synthetic biology and, 330, 331  
   *See also* *Saccharomyces cerevisiae*  
 Yervoy (ipilimumab), 694
- Z**  
 Z disc, 470, 471*f*, 472, 497  
*Zea mays* (corn), 11*t*  
 Zebrafish (*Danio rerio*), 11*t*, 18, 309*f*, 310*f*  
 Zydelig (idelalisib), 689*t*